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ABSTRACT 
Lichen planopilaris (LPP) and central centrifugal cicatricial alopecia (CCCA) are 
lymphocytic scarring alopecias. They share overlapping clinical and histopathologic 
findings. The goal of this dissertation has been to fmd reliably distinguishing features 
between these two conditions. Toward this goal, three different studies were conducted. 
Study 1 was a retrospective cross-sectional data analytic review of histologic features 
from patients identified by diagnosis of LPP or CCCA. Horizontal sections at level of the 
infundibulum, isthmus and inferior from scalp biopsies of 24 patients (19 CCCA and 5 
LPP) were analyzed. The findings of unaffected follicular units, retained sebaceous 
glands and mild perifollicular inflammation were found to favor the diagnosis of CCCA. 
Dilated eccrine glands and heavy perifollicular inflammation were found to favor the 
diagnosis of LPP. 
Vl 
Study 2 was a prospective cross-sectional data analysis study designed to identify and 
compare direct immunohistochemical findings in patients with LPP or CCC A. Vertical 
frozen sections of scalp biopsies from eleven patients ( 4 CCCA and 7 LPP) were stained 
with IgG, IgA, IgM, C3 and fibrinogen. No DIF finding that reliably distinguishes LPP 
from CCCA was found. The presence of a positive DIF was significantly correlated with 
the amount of inflammation. 
Study 3 investigated and compared T lymphocyte subsets, including T helper cells, 
cytotoxic T cells, Th 17 lymphocytes and regulatory T cells between LPP and CCCA 
cases. Subjects in this study were identical to study 2. There were no significantly 
distinctive T lymphocyte populations that differentiate between CCCA and LPP. There 
were higher numbers and percentages of CD8 positive cells in LPP compared to CCCA. 
The CD4:CD8 ratios were decreased in LPP and increased with duration of disease 
approaching proportions found in the normal hair follicle and CCCA. There were higher 
CD1a:CD3 ratios in LPP compared to CCCA. The CD1a:CD3 ratios in LPP decrease 
over time, approaching those found in CCCA. Results of this study confirm role of 
Langerhans cells as antigen presenting cells and role of cytotoxic lymphocytes in 
pathogenesis of LPP in early disease. Th17 lymphocytes and Tregs may have a role in 
both CCCA and LPP. 
Vll 
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INTRODUCTION 
Biology of the hair follicle 
Hair is found only in mammals, where its functional properties include 
thermoregulation, collecting sensory information, protection against environmental 
trauma, social communication , and mimicry.1 Human skin contains approximately 5 
million hair follicles, 100,000 of which are on the scalp. During one's lifetime, the 
average hair density on the scalp is the most when we are born (1 ,135/cm2). This 
decreases to 615/cm2 in adolescence and 435/cm2 in elderly adults.2 Hair density and 
volume are different among ethnicities . Caucasians have significantly higher hair density 
and volume compared to Asians and Mrican-Americans, respectively.3•4 
In utero, hair follicle formation begins on the head, and then moves downward to 
the remainder of the body. It is first visible on the eyebrow, upper lip and chin regions. 
Morphologically, hair follicle development has been divided into eight consecutive 
stages1•5 as shown in Figure 1. Each stage is characterized by unique expression patterns 
of growth factors and their receptors, growth factor antagonists, adhesion molecules, and 
intracellular signal transduction components. 1•5•6 
Stage 1 of hair follicle development first appears at 10 weeks gestation when 
collections of undifferentiated epithelial cells form epithelial placodes . In stage 2, 
epithelial placodes develop and expand vertically to form the primary hair germ. Dermal 
cells beneath the hair germ form a cluster, which later develops into a dermal papilla. In 
stage 3-4, the hair germ elongates into a cord of epithelial cells called a peg. The 
mesenchymal cells at the sides of the peg will develop into the fibrous sheath of the hair 
1 
follicle. In stage 5, the deepest portion of the follicle peg forms a bulbous structure, 
which surrounds the underlying mesenchymal cells destined to become the dermal papilla. 
Follicular keratinocytes begin to form the inner root sheath. At the same time, the 
follicular pigmentary unit generates melanin. 1•5•6 
In stage 6, the outer root sheath forms two bulges on the side of the hair follicle 
forrning an obtuse angle with the surface of the skin. The superficial bulge will develop 
into the sebaceous gland. The deeper bulge serves as the future site of epithelial stem 
cells that generate the new lower follicle during hair follicle cycling. The arrector pili 
muscle attaches in the bulge area. In the axillae, anogenital region, areolae, periumbilical 
region, eyelids, and external ear canals, a third bulge develops superficial to the 
sebaceous gland bud and gives rise to the apocrine gland. In stage 7, the necrosis and 
cornification of epithelial cells in the infundibulum form a central lumen, where the hair 
shaft will emerge in stage 8. 1• 5• 6 
There are three main types of hair follicles: lanugo, vellus and terminal, which 
share the same basic anatomy (Figure 2). However, their growth, size, shape, 
pigmentation, and other characteristics differ widely, based on body location and 
variation among individuals. Terminal hairs are typically greater than 60 J..Lill in diameter, 
possess a central medulla, and can grow to well over 100 em in length, depending on 
ethnicity. In contrast, vellus hairs are typically less than 30 J..Lill in diameter, do not 
possess a medulla, and are less than 2 em in length. The hair bulbs of vellus hairs in 
anagen are located in the reticular dermis, whereas hair bulbs of terminal hairs are in the 
subcutis . Terminal hairs are found on the scalp, eyebrows, and eyelashes at birth . Vellus 
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hairs are found elsewhere, and, at puberty, vellus hair follicles in the genitalia, axillae, 
trunk, and beard area in men transform into terminal hair follicles under the influence of 
sex hormones .6 
The first hairs formed in the embryo are lanugo hairs, which are non-pigmented, 
soft, and fine . Lanugo hair is typically shed between the 32nd and 36th weeks of 
gestation, although approximately one-third of newborns still retain their lanugo hair for 
up to several weeks after birth. After formation of lanugo hairs , terminal hairs and vellus 
hairs are formed. 1 
The hair follicle is divided into three major portions along its length, which are, 
from superficial to deep, the infundibulum, isthmus and inferior follicle. These portions 
are divided by the opening of sebaceous gland (Figure 3, upper arrow) and the insertion 
of arrector pili muscle, which is also called the bulge region (Figure 3, lower arrow). The 
length of each portion in the vellus and terminal hair follicle is shown in Figure 2. The 
infundibulum and isthmus portions are permanent, whereas the inferior portion changes 
with the hair cycle, regressing then regenerating via the activity of multipotent stem cells 
residing in the bulge region? These multipotent stem cells can repopulate the epidermis, 
hair follicles and sebaceous glands. Inflammatory alopecias that destroy the bulge region 
may lead to scarring alopecia or permanent loss of hair, due to loss of these stem cells.6 
The lowermost part of the inferior follicle forms a bulbous structure known as the 
hair bulb. The bulb epithelium surrounds a mesenchymal structure called the dermal 
papilla. The dermal papilla is comprised of fibroblasts, collagen bundles, a 
mucopolysaccharide-rich stroma and capillary loops. It has the ability to induce hair 
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follicle formation, and determines the size of the hair shaft. The volume of the dermal 
papilla correlates with the number of matrix cells, and thus the size of the hair shaft. 8 
The hair follicle is also divided circumferentially into layers, or compartments. 
From outermost to innermost these are the connective tissue sheath, the outer root sheath 
(ORS), the inner root sheath (IRS), the hair shaft cortex, and the hair shaft medulla 
(Figure 4). Each epithelial compartment expresses distinct hair follicle-specific keratins.9 
The connective tissue sheath is composed of type III collagen. It envelops the epithelial 
components of the hair follicle and is also continuous with the interfollicular basement 
membrane. 
The ORS is continuous with the epidermis at the infundibulum, continues to form 
the bulge at the base of isthmus and extends to the bulb. In the infundibulum, the ORS 
resembles the epidermis and forms a granular layer during keratinization. In the isthmus , 
the ORS keratinizes without a granular layer, so called trichilemmal keratinization. In the 
inferior follicle, the ORS cells are larger and paler due to abundant glycogen (Figure 5) . 
The functions of ORS include serving as a stem cell reservoir, a support and guidance 
structure for the IRS and hair shaft and as a transit route of nutrients and oxygen to the 
hair shaft via the IRS. The ORS also produces hair cycle-modulatory factors, such as 
fibroblast growth factor 5, neurotrophins and prolactin.10 
The IRS arises from hair matrix keratinocytes in the bulb. It consists of three 
separate layers, which from outer to inner are called Henle's layer, Huxley's layer and the 
IRS cuticle. The IRS, specifically Huxley's layer, dictates the shape of the hair by 
funneling the hair shaft cells as they are produced from the bulb.6 The IRS cuticle 
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attaches firmly to the hair shaft cuticle and desquamates at the mid isthmus (as shown in 
Figure 5B). The loss of the IRS below this point has been described as premature 
desquamation of the IRS, which is a feature of scarring alopecia.ll 
The hair shaft arises from hair matrix keratinocytes, which reside at the apex of 
dermal papilla (shown in Figure 6). It is composed of two layers, the hair cortex, which is 
the main structure of the hair shaft, and the hair medulla. The hair cortex consists of 
densely packed, spindle-shaped, fully cornified trichocytes. They are oriented 
longitudinally, parallel with the hair axis. The hair cortex is covered by the cells of the 
cuticle, which protect the shaft from weathering, fracture, breakage, and splitting.6 
During postnatal life, individual hair follicles perpetually cycle through three 
phases 12- 14: (i) intensive growth and hair shaft production (anagen), (ii) apoptosis-driven 
regression (catagen) and (iii) relative resting (telogen) as shown in Figure 1. 
Approximately 85-90% of scalp follicles are in anagen, 10-15% in telogen and less than 
1% in catagen. The length of anagen determines the final length of the hair shaft. 
Terminal scalp hair spends 2-6 years in the anagen phase, 2-3 weeks in the catagen phase 
and 3 months in the telogen phase. The anagen duration of vellus scalp hair is 6-12 weeks. 
There are substantial variations in anagen duration by part of the body. The anagen 
duration of moustache hair is 4-14 weeks, arms 6-12 weeks and legs 19-26 weeks. 12 
The formation of a new lower follicle in anagen phase begins with growth of the 
dermal papilla and increased mitotic activity in the overlying epithelium. This process is 
followed by formation of the hair bulb, and bulb matrix differentiation to follicular 
structures including the hair shaft. Once a telogen hair is dislodged, a new hair shaft 
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emerges up through skin surface and grows in a stable rate depending on the location of 
the hair follicle. The growth rate of terminal scalp hair is approximately 0.35 mm/day .6 
The catagen phase is a regression phase. It is characterized by apoptotic activity in 
lower portion of hair follicle, which is associated with a decrease in mitotic activity of 
matrix cells. The lower portion of hair follicle retracts upward, while the perifollicular 
sheath collapses and forms a fibrous streamer. The dermal papilla also moves upward and 
situates below the bulge at the lower portion of the isthmus. Pigmentation by melanocytes 
ceases, and leads to a non-pigmented end of the hair shaft. Once the catagen phase is 
complete, the lower portion of hair follicle becomes club shaped in the next phase, called 
telogen. The telogen phase is a so called resting phase, as mitotic activity of hair shaft is 
at its lowest and the hair shaft is ready for expulsion from the scalp . There is sometimes a 
lag period after shedding of the telogen hair and the formation of the next anagen hair, 
particularly in patients with androgenetic alopecia.15 
Other than anagen, catagen and telogen, a distinct phase of the hair follicle called 
exogen was described in 2002. The exogen phase is a unique shedding phase that differs 
from the shedding of the hair club found in telogen. The shedding activity of exogen is 
associated with increasing proteolytic enzymes, and it occurs in mid anagen phase. It is a 
highly controlled and timed event, which explains seasonal shedding in mammals and 
shedding of human hair following starting of medications such as minoxidil.16 
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Alopecia 
Loss of hair (alopecia) can lead to significant psychological and emotional 
distress, and it supports a multibillion-dollar pharmaceutical and cosmetic effort aimed at 
restoring hair . There are many causes of alopecia, and an accurate diagnosis is crucial to 
the prognosis and the determination of a treatment plan. The diagnosis is made by 
correlation of history , clinical findings, and histopathologic findings. Alopecia is 
categorized clinically as either focal or diffuse, and histopathologically by the presence or 
· absence of scarring. 
Non-scarring alopecia refers to hair loss without permanent destruction of the hair 
follicle. Examples include female and male pattern hair loss, telogen effluvium, alopecia 
areata, anagen effluvium, inherited disorders of the hair shaft, and hair breakage related 
to external factors. 
Scarring (cicatricial) alopecia refers to hair loss associated with inflammation, 
fibrosis and ultimately replacement of the hair follicle by scar tissue. Hair loss in scarring 
alopecia is permanent and the hair follicles may become completely destroyed. Examples 
include lichen planopilaris (LPP), central centrifugal cicatricial alopecia (CCCA), discoid 
lupus erythematosus, acne keloidalis, folliculitis decalvans, and dissecting cellulitis. 
Some alopecias demonstrate a biphasic pattern in which non-scarring alopecia is 
observed early and permanent hair loss appears later. These diseases include patterned 
hair loss, alopecia areata and traction alopecia. These forms of alopecia are classified as 
non-scarring , but after a long duration of active disease, permanent follicular drop-out 
occurs.17 
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Cicatricial alopecia 
Cicatricial alopecia is divided into primary and secondary forms. In pnmary 
cicatricial alopecia, the destruction of the hair follicle is caused by a targeted 
inflammatory process, which leads to permanent hair loss.ll , 18 These types of alopecia are 
categorized by the type of inflammatory cells present in the biopsy; those with 
neutrophils are called neutrophilic scarring alopecias, those with lymphocytes are called 
lymphocytic scarring alopecias. There is also a mixed group, as well as an end stage, non-
specific group. Each of these groups is further subdivided based on a classification 
scheme devised at a special workshop of The North America Hair Research Society17 
(NAHRS) as shown in Table 1. 
In secondary cicatricial alopecia hair follicles are destroyed nonspecifically as 
innocent bystanders, due to other diseases affecting the dermis. Example of diseases that 
can cause secondary scarring alopecia include cutaneous sarcoidosis, morphea, 
necrobiosis lipoidica and lupus vulgaris. 19 
While various forms of cicatricial alopecia have distinctive histopathological 
findings, an accurate diagnosis of cicatricial alopecia almost always requires good 
correlation of clinical and histopathological findings. This is because histopathological 
findings of some entities overlap and distinction between these entities can be 
exceedingly difficult. 
The diseases being studied in this dissertation are lichen planopilaris (LPP) and 
central centrifugal cicatricial alopecia (CCCA). They are in the category of lymphocytic 
scarring alopecia. There is currently no gold standard to distinguish these entities, and 
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although LPP .and CCCA overlap histologically, treatments for these disorders differ. It is 
thus essential to be able to distinguish them, not only for proper patient management, but 
also to further our knowledge on their pathophysiology. 
Lichen planopilaris 
Lichen planopilaris (LPP), a type of primary lymphocytic scarring alopecia, is 
also known as lichen follicularis or follicular lichen planus of the scalp ?0 • 21 Initially 
described in 1895 by Pringle, it is believed to be a follicular variant of lichen planus 
(LP)_, an extremely itchy eruption composed of purple, polygonal papules that have a 
predilection for the extremities and mucosal areas ?0 •2 1 
The 2003 NAHRS working classification of primary cicatricial alopecias17 
categorized LPP into three main clinical variants: classic LPP, frontal fibrosing alopecia 
(FFA) and Lassueur Graham-Little Piccardi syndrome. Others have proposed adding 
fibrosing alopecia in a pattern distribution (FAPD) as a presentation of LPP.22 
Classic LPP commonly involves the vertex, although any region of the scalp can 
be affected. The classic early findings are perifollicular violaceous erythema and 
perifollicular scales or keratotic plugs. After inflammation and hair shedding, scarring 
alopecic patches replace previously inflamed lesions. These are smooth surfaced, skin 
colored patches that may be patchy in a reticular pattern or become large, confluent areas 
of scarring alopecia?1 Careful inspection often reveals active perifollicular inflammation 
at the periphery. 
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The typical age of onset of classic LPP is around the fifth decade ?3 Women are 
more affected than men, arid account for 60 to 90% of cases?4 • 25 Caucasians are more 
affected than dark skinned individuals. Extra.,.cranial lichen planus involving nails, 
mucous membrane and glabrous skin, may occur. The reported rate of extra-cranial 
involvement was variable, ranging from 17 to 50% of patients . 20• 26 
FFA is a variant of LPP seen mostly in postmenopausal women, and rarely in 
men.27 It presents as a progressive symmetrical band of scarring alopecia affecting the 
frontal hairline, the preauricular scalp and the retroauricular scalp. Eyebrows are often 
affected before the scalp, and inflammation in this area is generally absent or subtle. 
Facial papules may be observed.28 
Lassueur Graham-Little Piccardi syndrome consists of scarring patchy alopecia of 
the scalp, non-scarring axillary and pubic hair loss, and a lichenoid follicular eruption on 
the body, scalp, or both. Scalp alopecia often precedes follicular papules?9 • 3° FAPD 
presents with perifollicular erythema and scales as is commonly seen in classic LPP, but 
it involves an area on the crown of the scalp that is seen in female pattern hair loss?2 • 31• 32 
FAPD is often underdiagnosed early in the disease, and requires histopathologic 
confirmation. 
Pathophysiology of LPP 
The etiology of lichen planopilaris is unknown, but it is presumed to be a cell-
mediated immune reaction, similar to lichen planus. In active lesions of LPP, there is an 
inflammatory process mediated by T lymphocytes (CD4 and CD8 positive), supporting 
10 
the notion that cell-mediated immunity plays a major role in the triggering the clinical 
expression of the disease.33 ' 34 These lymphocytes attack and destroy particular antigens 
on keratinocytes in follicular epithelium. As a result of follicular epithelial destruction, 
the hair cycle is disrupted causing alopecia. The inflammation is mostly located around 
the bulge area where multipotential stem cells are present; their destruction leads to 
permanent loss of the follicles _34 • 35 
The nature of targeted follicular antigens is unknown. The antigen may be an 
autoreactive peptide, thus classifying LPP as an autoimmune disease. Alternatively, it 
may represent an exogenous antigen such as a medication, a contact allergen, an 
infectious agent, or an unidentified immunogenic target. Medications that induce LPP 
include etanercept and infliximab, which are both anti-tumor necrosis factors used for 
treatment of psoriasis ?6• 37 A series of patients with LPP occurring years after hair 
transplantation for male pattern hair loss have been reported. The possible explanations 
for this phenomenon include koebnerization, whereby a condition develops or spreads 
due to trauma, and immune privilege collapse, whereby the hair follicle, previously 
unrecognized by the body's immune system, becomes subject to attack.38 •39 
The possible etiologies of LPP other than cell-mediated immunity include altered 
follicular integrin expression in the hair follicle40 and decreased expression of peroxisome 
proliferator-activated receptor garnma4 1 (PPARy). Integrin is a transmembrane receptor 
found on all animal cells. It mediates the attachment between a cell and its surroundings 
and also transduces signals between cell and extracellular matrix. Altered integrin 
distribution at the basement membrane of follicular epithelium has been shown in active 
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LPP lesions, but not in normal follicles.40 This may cause the affected areas to be more 
susceptible to antigen presentation, and the resultant immune response could explain the 
phenomenon of easy epilation of anagen hairs with an abnormal gelatinous root sheath 
that is seen in active scarring alopecia. 
PPARy is a member of the nuclear receptor super-gene family, which regulates 
the expression of genes involved in inflammation and lipid homeostasis. It was recently 
shown to have a role in the pathogenesis ofLPP.41 "42 A significantly decreased expression 
of multiple genes required for fatty acid oxidation, cholesterol biosynthesis, and 
peroxisome biogenesis, including PP AR y, were identified in LPP scalp tissue .41-43 
Moreover, targeted knockout of PP AR y in the stem cells of the bulge causes scarring 
alopecia.41 ' 43 Thiazolidinedione, a PPARy agonist, has been shown to improve clinical 
symptoms, decrease perifollicular erythema, halt the spread of old patches and decrease 
inflammatory infiltration in LPP patients.43 •44 
Clinical presentation of LPP 
The clinical course and pattern of hair loss in LPP may be insidious or fulminant, 
and the pattern of hair loss on the scalp is highly variable. Most commonly there are 
several scattered foci of partial hair loss on the crown. Disease activity is best appreciated 
at the periphery of active lesions, which exhibit characteristic perifollicular erythema and 
follicular hyperkeratosis ?0 The inflammation affects the anchoring of anagen follicles, 
and they can be pulled out easily in active lesions. Eventually scattered foci of complete 
hair loss form, and sometimes merge to form large areas of hair loss. Late lesions Jack of 
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erythema and scale, and close inspection reveals loss of follicular orifices on the scalp 
surface. The sites of predilection in classic LPP are the frontocentral scalp and crown. 
Associated cutaneous, nail, and mucous membrane lichen planus may be present in one 
third to half of cases?1• 24 ' 25 ' 45 LPP may be asymptomatic, but scalp pruritus and 
dysesthesia (pain, discomfort and burning) are often present. 
Histopathologic findings of LPP 
Histopathologic findings vary according to the stage of the disease. Early on there 
is a lichenoid lymphocytic infiltrate affecting the infundibulum and isthmus, sparing the 
lower portion of hair follicle ?0• 2 1' 25 Interface dermatitis occurs between the follicular 
epithelium and adjacent dermis with loss of the basement membrane zone. Sebaceous 
glands are lost in early lesions and the root sheaths of the hair follicles are destroyed. 
There is no increase in dermal mucin and abnormal changes in the structure of the 
vascular plexus as in discoid lupus erythematosus. Later on, extensive perifollicular 
lamellar fibrosis develops, especially around the isthmus. In end stage disease , hair 
follicles are completely replaced by fibrosis and it is not possible to distinguish LPP from 
other primary cicatricial alopecias. 20 ' 21 ' 25 Several studied have been published on the use 
of elastic fiber abnormalities in LPP ,46 ' 47 including wedge shape loss of elastin in the 
upper dermis. 
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Central centrifugal cicatricial alopecia (CCCA) 
CCCA is a progressive primary lymphocytic scarring alopecia of the central scalp 
that occurs primarily in African American women.48 ' 49 It was first described in 1968 by 
Lopresti et al50 , as "hot comb alopecia" based on the hypothesis that heat from hot 
combing was responsible for the alopecia. The term "follicular degeneration syndrome" 
was later proposed in 1996, as no etiological relationship between use of a hot comb and 
the scarring alopecia was found.51 Other terms including, scarring alopecia in African 
Americans and chemically induced cosmetic alopecia were also proposed.52 Finally, the 
term "central centrifugal cicatricial alopecia" was proposed by Sperling19 in 2000 and 
adopted by the North American Hair Research Society in 2001.17 
CCCA is the most common type of primary scarring alopecia in Mrican 
American women. Women are more affected than men with a ratio of 4:1 or more.53-55 
The mean age of presentation is 36 years in females and 31 years in males. The 
prevalence is estimated as high as 5.6%-17% of the African American population. 53-57 
Pathophysiology of CCCA 
The etiology of CCCA is unknown. It is hypothesized that it is multifactorial, 
incorporating a genetic predisposition with follicular damaging hairstyles .57 Genetic 
predisposition may leave the hair follicle predisposed to external injury, and the use of 
hair relaxers, traction, or other chemicals might create irritation, inflammation and 
resultant scarring alopecia. However, reports of familial cases without any evidence of 
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mechanical or chemical damage to the hair question the contribution of styling practices, 
and strengthen the role that genetics plays in CCCA.56' 58 
Follicular damaging hairstyles are strongly associated with CCCA.59' 60 These 
include the use of hair weaves, cornrows, braided hairstyles and artificial hair extensions. 
These hairstyles may cause chronic chemical irritation or mechanical trauma to the 
structure of the hair follicle and the follicular stem cells, and result in permanent 
destruction of hair follicles .59 
Altered retinoid metabolism has been recently proposed as an etiology for 
CCCA.61 Retinoic acid and retinoid metabolism have critical roles in the development 
and maintenance of multiple epithelial tissues, including skin, hair, and sebaceous 
glands.56•62 These include maintenance of hair growth and hair cycling.56 ' 63 A recent study 
has shown an association of altered retinoid metabolism with cicatricial alopecia similar 
to CCCA in a mouse model. 56 In humans, many retinoid metabolic proteins are altered in 
mild CCCA.56 Furthermore, retinoid supplementation in patients with low serum retinol 
levels has been shown to improve CCCA.61 
Clinical presentation of CCCA 
CCCA presents as a roughly circular alopecic patch at the crown and/or vertex of 
the scalp, which develops over time and gradually progresses centrifugally .49 ' 55 ' 64 Similar 
to other scarring alopecias , the affected scalp ultimately becomes smooth and shiny , with 
loss of follicular openings. A few short brittle hairs may remain. The most active disease 
is at the periphery. Eventually the disease becomes quiescent.49 Dysesthesia (mild 
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pruritus, pain, or tenderness) may occur in involved areas but is usually not severe, and 
symptoms may be trivial or absent. 
Histopathologic findings of CCCA 
An early histologic change of CCA is lymphocytic infiltration of the upper 
follicle, from the lower follicular infundibulum to the upper isthmus.49-52 Concentric 
lamellar fibroplasia occurs around the mid to upper follicle. Sebaceous glands are lost, as 
in other types of scarring alopecia. A mild perivascular lymphocytic infiltrate may be 
present. The number of terminal hair follicles is decreased and there is an increase in the 
number of fibrous tracts, reflecting loss of hair follicles. Interface alteration at the derma-
epidermal junction and around the hair follicle, dyskeratotic cells , mucin and perieccrine 
inflammation are usually absent. 49 
In the normal hair follicle, the IRS attaches firmly to the hair shaft as it arises 
from the hair matrix then desquamates at the level of sebaceous gland opening or 
isthmus .1 The loss of the IRS below this point has been described as premature 
desquamation of the IRS (PDIRS). It is found in association with perifollicular 
inflammation in some cases of primary scarring alopecias, as result the result of cell-
mediated injury or trauma.65 ' 66 Although it is nonspecific , it is hypothesized that 
premature desquamation of inner root sheath occurs early in CCCA before marked 
inflammation or degenerative follicular changes, and its finding early is distinctive to the 
diagnosis of CCCA.66 
Perifollicular inflammation m CCCA may cause changes in follicular unit 
morphology, forcing the follicular canal into an eccentric position and causing follicular 
16 
asymmetry. Progressive thinning of the external root sheath leads to follicular distention, 
rupture, hair granulomas and dense fibrosis.49 The end stage changes , however, are 
indistinguishable from other primary scarring alopecias. Verhoeff-Van Gieson staining 
for elastin in CCCA has shown broad fibrous tracts with intact elastic sheath and thick 
elastic fibers throughout the dermis .47 
The distinction of LPP and CCCA 
LPP and CCCA are two of the most common lymphocytic scarring alopecias. 
They have distinctive clinical features and occur in different groups of populations, LPP 
in Caucasian and Hispanic and CCCA in African American. CCCA usually starts at the 
vertex or crown then progress centrifugally , whereas LPP is typically patchier in 
distribution, although it can become confluent on the crown. In patients in whom the 
clinical presentation is not characteristic, a biopsy is required. While a biopsy can 
distinguish LPP from other lymphocytic scarring alopecias such as discoid lupus 
erythematosus (DLE) , Mirmirani et al. have suggested that LPP is histologically 
indistinguishable from CCCA.18 Thus , clinico-pathological correlation is always required 
in making these diagnoses. Recent study by Elston et al. 47 suggested the use of EVG to 
differentiate LPP and CCCA, wedge shape scars in LPP and broad fibrous tracts with 
intact elastic sheath in CCCA.47 
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Direct immunofluorescence in LPP and CCCA 
Immunofluorescence staining is an immunohistochemical technique using 
fluorescent dye labeled antibodies to identify antigens, such as antigens on the surface of 
bacteria, or antigens in cells in histologic sections or in other specimens. In cutaneous 
disease, the antigen in question is usually an antibody itself, and fluorescent-labeled 
antibodies are used to detect them either in the blood (indirect immunofluorescence) or in 
tissue sections (direct immunofluorescence). In indirect immunofluorescence, a control 
tissue is chosen as a substrate, and a fluorescent-labeled antibody is used to detect 
circulating antibodies in the patient' s serum after it is applied to the substrate. In direct 
immunofluorescence (DIF), the fluorescent labeled antibodies are applied directly to the 
patient' s tissue , to detect antibodies deposited there. Once the fluorescent-labeled 
antibody interacts with antigen of interest, it can be visualized using a special microscope 
that emits ultraviolet light. 
DIF is routinely performed in many dermatologic disorders to identify 
immunoglobulins deposited in different layers of affected skin. In immunobullous 
diseases such as pemphigus vulgaris and bullous pemphigoid, DIF is used diagnostically 
to determine whether autoantibodies and complement are deposited within the epidermis 
(pemphigus) or at the dermoepidermal junction (pemphigoid). DIF is also used in 
collagen vascular diseases such as lupus erythematosus, where multiple immunoglobulins 
and complement are found at the dermoepidermal junction. It is occasionally used in 
inflammatory skin conditions such as lichen planus. However, there are only a handful 
studies on the use ofDIF in the diagnosis ofLPP21' 25 •26•67 and none on CCCA. 
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In LPP and CCCA, the possible locations where immunoglobulins can be 
deposited are the basement membrane zone (BMZ) of the hair follicle, around the 
vasculature, and on apoptotic keratinocytes, also called colloid bodies, at the DEJ. 
Typically, fluorescent tagged antibodies against IgG, IgM, IGA, C3 and fibrinogen are 
used. The pattern can be linear, granular or speckled. 
Immunoperoxidase staining 
Immunoperoxidase staining 1s an immunohistochemical technique that uses a 
peroxidase-catalyzed reaction to visualize antibodies that bind with antigens of interest. It 
is used to determine the presence, intensity and quantity of a particular antigen. The first 
step is the binding of the specific (primary) antibody to the cell or tissue sample, usually 
prepared and fixed on a slide. The detection of the primary antibody can be then 
accomplished directly with a secondary antibody labeled with a peroxidase enzyme, 
which is used to catalyze a chemical reaction to generate a colored product. An example 
of the peroxidase staining is diaminobenzidine (DAB) method, which was used in our 
study. It visualizes the presence of enzyme-antibody-antigen complex fixed to tissue as a 
stable brown product. 
In clinical diagnostics, immunoperoxidase staining can be used on a tissue biopsy 
for a more detailed histopathologic study, including sub-classifying tumors and lineage of 
lymphocytes. In dermatopathology, immunoperoxidase staining is used to differentiate 
carcinoma, melanoma, sarcoma, neural neoplasms and lymphoma. A panel of antibodies 
is generally recommended rather than a single stain. 
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Immunoperoxidase staining is not used in the diagnosis of alopecia, but it has 
been useful as a research tool, to identify subtypes of inflammatory cells and to better 
understand disease pathogenesis. In alopecia areata, a non-scarring alopecia exhibiting 
lymphocytes at the bulb area, CD8 positive T-cells and Thl cytokines were found to play 
a key role in the autoimmune attack that occurs in this disorder .68 In primary scarring 
alopecia, loss of stem cell markers (CK15, CD34 and nestin) is related to permanent 
follicular damage.69 In DLE, CD8 positive T-cells were increased in patients with 
scarring disease.70 In LPP, immunoperoxidase staining identified both CD4 and CDS 
positive T-cells, which were activated by Langerhans cells that are increased in the 
dermis and epidermis?5 This finding suggested a cell-mediated autoimmune process to a 
specific antigen in LPP. CCCA is known as a lymphocytic scarring alopecia , however, 
the role ofT-cells and Langerhans cells has not been elucidated. 
PURPOSE OF THE STUDY 
It has been shown that scarring alopecia affects the quality of life of its sufferers, 
regardless of age or extent. A recent symposium brainstormed on the future direction of 
cicatricial alopecia research and identified a better classification system as one of its 
goals. LPP and CCCA are diseases with overlapping clinical and histopathologic 
findings. A study to better define the histopathologic characteristics of LPP and CCCA 
was initiated. Direct immunofluorescent features and subtypes of inflammatory cell 
populations using immunoperoxidase staining in both diseases in hopes of furthering our 
understanding of these conditions were studied. It is our hope that a better delineation of 
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these entities under the microscope will lead to further insight into their pathogenesis and 
hopefully increased therapeutic options. 
Several histologic features that might distinguish LPP from CCCA under the 
microscope were evaluated. The features of the hair follicles were evaluated, including 
the number of follicles, both terminal and vellus, and the presence and number of 
follicular units, which are groups of sebaceous glands and hair follicles at the level of the 
isthmus . In alopecia, hair follicles are reduced in number, sebaceous glands are 
destroyed, there is thinning of follicular epithelium and follicular asymmetry, and there 
can be premature desquamation of the inner root sheath. The inner root sheath normally 
presents and desquamates at the isthmus level, just below the entry of the sebaceous duct. 
Premature desquamation of the inner root sheath (PDIRS) is said to occur when the inner 
root sheath desquamates at a lower level 
The pattern and degree of perifollicular and perivascular inflammation were 
evaluated. The types of inflammatory cell were noted, as was the location, anatomic 
level, pattern and density of the inflammation. Associated findings such as individually 
necrotic keratinocytes and lymphocytes within the follicular epithelium were recorded. 
Individual necrotic keratinocytes (INKers) are a feature of interface dermatitis , and their 
presence in follicular epithelium has been described in lymphocytic scarring alopecia.11 
Subsets ofT -lymphocytes and Langerhans cells were quantified using immunoperoxidase 
staining. 
The last histologic feature evaluated was the presence and patterns of fibrosis and 
scarring . Destruction of the hair follicle leaves a scar where the hair follicle once stood, 
21 
which is also called a fibrous or fibrotic tract. It is the replacement of the follicle by 
amorphous connective tissue, which signifies follicular dropout.71 • 72 Naked hair shafts 
may be present in fibrotic tracts, which are hair shafts without any epithelium, sometimes 
surrounded by multinucleated giant cells forming a foreign body granuloma.71 These 
were searched for and quantitated at different levels of the hair follicle. The presence or 
absence of perifollicular mucin was noted, which was hypothesized to be related to the 
chronicity of the perifollicular fibrosis ?3 Of note, fibrous scars found in cicatricial 
alopecia are different from follicular streamers found in non-scarring alopecia. These 
streamers, also known as follicular stelae, are elastin rich angiofibrotic whorls of 
. connective tissue, remnants of a follicle that has cycled from anagen to catagen/telogen. 
They are a crucial element in hair cycling, as they serve as the mesenchymal column 
leading to new follicular papilla formation . This serves as the pathway for downward 
regrowth of a new anagen follicle. 
Lastly , we used DIF and immunoperoxidase staining to see if there are features 
that distinguish LPP from CCCA, as there are few studies on the former, and no reported 
studies on the latter. 
HYPOTHESES AND SPECIFIC AIMS OF THE STUDY 
The study was based on three hypotheses: one, that there are histologic features 
that distinguish LPP from CCCA; two, that there are DIF features that distinguish LPP 
and CCCA, and three, that there are different populations of inflammatory cells that 
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distinguish LPP from CCCA. The specific aim of the study was to identify distinguishing 
findings between LPP and CCCA. 
RESEARCH DESIGN 
Two research protocols were designed. The first protocol was designed to answer 
the first hypothesis. It was a retrospective, cross-sectional data analytic review of 
histologic features from patients diagnosed with either LPP or CCCA from a data 
repository of alopecia patients (Hair Data Repository, IRB# H-27150, PI Dr. Goldberg) 
and the records of the Skin Pathology Laboratory at Boston University between January 
1 , 2000 and December 31 , 20 11 . 
The second protocol was designed to answer the second and the third hypotheses. 
It was a prospective, cross-sectional data analytic study, designed to identify 
immunofluorescent and immunohistochemical features that distinguish between LPP and 
CCCA. 
STUDY 1. The histopathologic distinction between lichen planopilaris and central 
centrifugal cicatricial alopecia 
Study 1. Materials and Methods 
A retrospective, cross-sectional data analytic review was conducted. The study 
was approved by the Institutional Review Board (IRB) at the Boston University Medical 
Center (BUMC) under protocol number H-31124. Dr. Goldberg's Hair Data Repository 
and records of the Skin Pathology Laboratory at Boston University were used to select 
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patients diagnosed with either LPP or CCCA between January 1, 2000 and December 31 , 
2011. All selected patients underwent chart review, and those that were clinically 
evaluated and biopsied by Dr. Goldberg were included in the study. Patients with 
exclusion criteria (see below) were excluded. 
Nineteen cases of CCCA and five cases of LPP were studied. Investigators were 
blinded from the diagnosis at time of slide review. The form used to collect data can be 
found in the Appendix 1. In each case, we reviewed all available consecutive horizontal 
sections to find the levels of interest for data collection, which included the isthmus and 
the inferior follicle. The isthmus level is the level where sebaceous glands are largest in 
cross section, and hair follicles are normally grouped with sebaceous glands in follicular 
units. The inferior follicle level chosen was the dermal subcutaneous junction, where 
there is an equal amount of dermal collagen and subcutaneous tissue. 
Data on select histopathologic features that we thought might contribute to 
distinguishing CCCA from LPP at both the level of the isthmus/infundibulum and the 
inferior follicle was collected. At the isthmus/infundibulum, these included the presence 
of epidermal involvement, the number of hair follicles, the number of fused follicles, and 
the number of normal follicular units. Fused follicles are conjoined follicles with a shared 
follicular epithelium. The numbers of fibrous tracts were categorized as absent, 1-5, 6-10 
and >10. 
To grade the degree of follicular asymmetry, the thickest part of the outer root 
sheath was evaluated and compared it to what estimated normal thickness would be for 
that follicle. A follicle where the thickest part of the outer root sheath was over twice 
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normal was considered severely asymmetric, over 1.5 times normal was considered 
moderately asymmetric, and between 1 and 1.5 times normal was considered mildly 
asymmetric. To grade the degree of perifollicular fibrosis , the diameter of the fibrosis 
with the diameter of the outer root sheath was compared. If the fibrosis was thicker than 
the thickness of the outer root sheath, it was considered severe, if it was over half the 
thickness of the outer root sheath it was considered moderate, and if it was less than half 
the thickness of the outer root sheath it was considered mild. 
Mucin, naked hair shafts, INKers and intrafollicular lymphocytes, and plasma 
cells were recorded as present or absent. Perifollicular · inflammation was considered 
present if it involved at least half the circumference of the hair follicle. It was considered 
marked if it was thicker than the thickness of the outer root sheath, moderate if it was 
over half the thickness of the inner root sheath, and mild if it was less than half the 
thickness of the outer root sheath. Perivascular inflammation was graded similarly. It was 
considered either mild or moderate, depending on its approximate thickness in 
comparison to the outer root sheath. Moderate inflammation was thicker in diameter than 
the outer root sheath, and mild inflammation was thinner in diameter than the thickness 
of the outer root sheath. 
Similar data was collected from the inferior follicle at the dermal-subcutaneous 
junction, adding the presence or absence of naked hair shafts. During data collection 
dilation of eccrine ducts was noted, and this finding was added to the list of histologic 
features being collected. 
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Once data collection was complete, the medical records of the patients were 
reviewed for relevant information including patient age, sex, ethnicity, age at the time of 
biopsy and duration of disease prior to biopsy. Once unblinded, the data was separated 
into the two groups of CCCA and LPP. The diagnosis was made on the basis of the 
clinical presentation. Then statistical analysis was done to identify distinguishing features 
of the two diseases. 
Study 1. Inclusion and Exclusion Criteria 
Patients who have been evaluated and biopsied by Dr. Goldberg and found to 
have a diagnosis of either LPP or CCCA from January 1, 2000 to December 31, 2011 
were included. Exclusion criteria included patients whose biopsy slides were not 
available, those whose slides were cut in vertical sections, those whose slides had 
inadequate tissue (lacking epidermis or the dermal subcutaneous junction), those that 
were coded as scarring incorrectly, and those whose scarring alopecia was end-stage (less 
than three remaining hair follicles in one horizontal section of 4 mm. punch biopsy). 
Study 1. Sample Size 
The study sample was obtained from two sources. Patients with either LPP or 
CCCA were identified in the Hair Data Repository and from the records of the Skin 
Pathology Laboratory at Boston University. The Hair Data Repository identified 9 patient 
biopsies of LPP and 27 of CCCA. The Skin Pathology Records revealed additional 9 
biopsies of LPP and 18 of CCCA, for a total of 18 LPP biopsies and 45 of CCCA. Many 
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biopsies met exclusion criteria (Fig. 1), leaving 5 available biopsies of LPP and 19 of 
CCCA. The most common exclusion was that the slides were cut vertically rather than 
horizontally, followed by insufficient tissue (chosen levels not available) and inadequate 
numbers of follicles due to end-stage disease. Three patients were excluded because their 
slide review revealed non-scarring alopecia. 
Study 1. Data Analysis 
Statistical analysis was performed using R, Statistical Software, version 2.14.1 
(2011-12-22) and AnalystSoft Inc., StatPlus: Mac, version 2009. Quantitative variables 
were calculated in mean, minimum and maximum. T -test was used for intergroup mean 
comparison. Qualitative variables were calculated in percentages and Fisher exact test 
was used for intergroup comparison. A p-value of less than 0.05 was considered 
statistically significant (Figure 7). 
Study 1. Results 
The demographic data of both groups is shown in Table 2. Most patients were 
female, with the exception of one male patient with CCCA. All CCCA patients were 
African American, while LPP patients were Caucasian or Hispanic. About 80% of 
patients in both groups were between 30-60 year old, with 2 cases of CCCA who were 
under 30 years old and one case of CCCA over 60 years of age. The mean age of the LPP 
group was higher than the CCCA group, 49.4 and 44.3 year old, respectively. The mean 
duration of disease prior to the biopsy in the CCCA group was highly variable from 1 to 
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20 years with a mean of 7.4 years, whereas in the LPP group, the duration of disease prior 
to biopsy ranged from 1 to 10 years with a mean of 3 .8 years. 
The numbers of follicles at the isthmus and inferior level are shown in Table 3. 
The mean number of follicles in the LPP group was higher than in the CCCA group at the 
isthmus and inferior level. Most follicles in the LPP group were terminal, with a ratio of 
terminal to vellus follicles of 11:1. The ratio of terminal to vellus follicles in CCCA 
group was 7:3. The ratio of terminal to vellus hair in LPP is higher than in the CCCA 
group. However, there was no significant difference in the number of follicles between 
the two groups. The numbers of fibrous tracts at the isthmus and inferior level can be 
found in in Table 4. There was no difference in the mean number of fibrous tracts 
between CCCA and LPP at either level. 
Selected histologic findings in the two diseases can be found in Table 5 . There 
was no epidermal hyperplasia, interface dermatitis or hypergranulosis in any patient in 
either group . We found the absence of normal follicular units in all LPP cases and in 
some cases of CCCA (42%), which was statistically significant (p<0.05). There was 
complete loss of sebaceous glands in 60% of the LPP group but only in 11% of the 
CCCA group. The difference was statistically significant (p<0.05) . 
Fused follicles were found more at the isthmus level compared to the inferior 
level. At the level of isthmus, fused follicles were found in some cases with CCCA and 
in almost all LPP cases, 52% and 80% respectively . At the inferior level, a fused follicle 
was found in only one case, which was LPP. There was no difference in the presence of 
fused follicles between CCCA and LPP at either the isthmus or inferior level. 
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Premature desquamation of the inner root sheath was found in most cases of 
CCCA and LPP, 74% and 60% respectively, with no statistical significance . Dilated 
eccrine glands were found in 10% of the CCCA group compared to 60% of the LPP 
group (p<O .05). 
More follicular INKERs at the inferior level compared to the isthmus level were 
observed in both groups. At the level of isthmus, follicular INKERs were seen in 31 .6% 
of the CCCA group and 40% of the LPP group. At the inferior level follicular INKERs 
were found in 52% of the CCCA group and 100% of the LPP group (n.s.). 
More naked hair shafts were noted at the inferior level compared to the isthmus 
level. The presence of naked hair shafts was found more often in LPP cases compared 
to CCCA cases. These were present in 60% of LPP patients and 16% of CCCA patients 
at the level of isthmus, and 60% and 37%, respectively, at the inferior level (n.s.). 
More intrafollicular lymphocytes at the isthmus level were found compared to the 
inferior level. At the isthmus level, intrafollicular lymphocytes were found in 60% of 
LPP cases and 37% of CCCA cases. At the inferior level, no intrafollicular lymphocytes 
were seen in any cases (n.s.). 
The number of plasma cells was more at the isthmus level when compared to the 
inferior level. Plasma cells were found more often in CCCA cases compared to LPP, 
68% and 20% at the isthmus level and 24% and 0% at the inferior level (n.s.). Mucin 
was found more often at the level of isthmus compared to the inferior level. Mucin was 
observed in 68% of CCCA cases and 20% of LPP cases at the level of the isthmus, in 
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24% of CCCA cases and in none of the LPP cases at the inferior level. However, the 
difference was not statistically significant. 
Data on follicular asymmetry can be found in Table 6, and examples of follicles 
with mild asymmetry and marked asymmetry can be found in Figure 8. Most cases of 
CCCA and LPP had mild follicular asymmetry, 79% and 60% respectively at the isthmus 
level and 53% and 60% at the inferior level. There was no statistically significant 
difference in follicular asymmetry between the two groups. 
Data on perifollicular fibrosis can be found in Table 7. At the isthmus level, most 
cases of CCCA had mild and moderate perifollicular fibrosis, whereas most cases of LPP 
had moderate perifollicular fibrosis. At the inferior level, most cases of CCCA and all 
cases of LPP had mild perifollicular fibrosis. Results from both isthmus and inferior 
levels were not significantly different. 
Data on the amount of perifollicular inflammation can be found in Table 8. At the 
isthmus level, we found that most CCCA cases had mild or absent perifollicular 
inflammation (89.4%), whereas most (60%) LPP cases had moderate or severe 
perifollicular inflammation. This difference was statistically significant (p=0.04) . At the 
level of the inferior follicle, mild or absent perifollicular inflammation was noted in most 
cases of both CCCA and LPP (89 .4% and 80%) with no significant difference. 
The degree of perivascular inflammation can be found in Table 9. At the isthmus 
level, we found that most CCCA cases (68%) had mild perivascular inflammation, 
whereas LPP cases had variable perivascular inflammation, with 20% of cases having 
none, 40% mild, 40% moderate. There was no significant difference between the degree 
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of inflammation in CCCA and LPP at the isthmus level. At the inferior level, most cases 
of both CCCA and LPP had no perivascular inflammation, although some cases had mild 
perivascular inflammation, with no significant difference. 
Study 1. Discussion 
In 1968, Lopresti et al.50 described the histologic findings of CCCA, called "hot 
comb alopecia" at that time, as superficial perifollicular lymphocytic infiltrate with 
degeneration of ORS , epidermal atrophy with elongated rete ridges, with fibrotic 
replacement of the follicular unit sparing the arrector pili muscle. In 1992, Sperling and 
Sau51 proposed the term "follicular degeneration syndrome" (FDS) and described 
additional, unique findings that they felt were not found in other scarring alopecias, 
including premature desquamation of the IRS and migration of the hair shaft through the 
ORS. Other histologic findings found in, but not limited to, CCCA include a 
mononuclear cell infiltrate and lamellar fibroplasia at the level of the isthmus, 
disintegration of the follicular epithelium, "naked" hair shafts with surrounding foreign 
body giant cell reaction, and replacement of the entire follicle by thick fibrous tracts .51 In 
1993 , Nicholas et al.52 described histologic findings similar to those previously described 
in hot comb alopecia and FDS, with perifollicular chronic inflammatory cells, 
perifollicular fibrosis in a lamellar pattern, naked hair shafts within the dermis, and 
eventual total replacement of hair follicles by fibrosis. They described these findings 
under the term "chemically induced cosmetic alopecia". 
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Similar to what was previously reported in CCCA cases, a decrease in density of 
terminal and vellus follicles, a decreased or absent number of normal follicular units, 
perifollicular lymphocytic inflammation with perifollicular mucinous fibrosis, PDIRS, 
loss of sebaceous glands, a decreased number of normal follicular units, follicular 
epithelial thinning, follicular asymmetry, naked hair shafts, plasma cells, increase fibrotic 
tracts and fusion of follicular epithelium of several follicles. In contrast to Lopresti, 
epidermal atrophy or elongated rete ridges was not seen. INKERs and lymphocytes 
within the follicular epithelium were found in some cases. 
In 1996, Headington57 - described PDIRS as a non-specific finding present in a 
variety of scarring alopecias. Headington also described histologic findings similar to 
those described by Sperling and Sau, including primary follicular scarring with decreased 
follicular density, loss of sebaceous epithelium, follicular fusion and slight perivascular 
lymphocytic inflammation. Late-stage lesions were characterized by destruction of 
pilosebaceous units, dermal scarring, and dermal lymphocytic and plasma cell infiltration. 
The concept that PDIRS was not a specific finding in CCCA was supported by 
Horenstein and Simon in 2007.65 However, Sperling proposed in 2007 that PDIRS as an 
early finding, without significant inflammation or fibrosis, is distinctive of CCCA.66 
PDIRS was observed in 74% of patients with CCCA cases and 60% of patients 
with LPP, consistent with Headington's and Horenstein and Simon's assertion that this 
finding is non-specific for any particular cicatricial alopecia. This is probably the result of 
cell-mediated injury to the follicular epithelium.65 PDIRS was not found in LPP cases 
with duration of disease less than 2 years or with no perifollicular inflammation. 
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However, PDIRS was seen in many cases of CCCA with duration of disease less than 2 
years , even with absent perifollicular inflammation. Our findings support Sperling's 
assertion that the presence of PDIRS in early lesions without significant inflammation is 
distinctive of CCCA. 
The histopathologic findings of LPP were described by Ackerman et al. in 1988 
as compact orthokeratosis, zones of hypergranulosis around hair follicles , and a band-like 
infiltration of lymphocytes ?4 In 1992, Mehregan et al.21 studied 45 cases of LPP and 
described perifollicular lymphocytic inflammation at the infundibulum and isthmus, · 
which, in most cases, did not involve every hair follicle. Loss of elastic fibers, follicular 
plugging, vacuolar degeneration of the ORS, cytoid bodies and fibrosis were found in 
over 50% of cases. Interfollicular epidermal involvement was found in less than 10% of 
cases. In 2003, Chieregato et al.25 reported findings from 30 cases of LPP, described as a 
band-like lymphocytic infiltrate with destruction of the follicular basement membrane 
and the ORS between the infundibulum and isthmus. They also described 
hypergranulosis, hyperkeratosis, acanthosis, degeneration of basal keratinocytes and 
destruction of epidermal basement membrane in the epidermis. In chronic lesions , they 
found a basophilic fibrous stroma with reduction of sebaceous glands and arrector pili 
muscles and the presence of colloid bodies. 
In 2008, Tandon et al .Z0 reviewed 27 LPP cases and reported lymphocytic 
perifollicular and perivascular inflammation, marked reduction of hair density with loss 
of vellus hairs, reduction or complete absence of arrector pili muscles, and complete 
absence of sebaceous glands of involved follicles (in most cases). Contrary to other 
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reports, they found PDIRS in only one case, follicular plugging in a few cases and no 
significant interfollicular epidermal change. They also described mucinous perifollicular 
fibroplasia in one third of cases. 
In this study, LPP cases were found to have moderate to severe perifollicular and 
perivascular lymphocytic inflammation with perifollicular mucinous fibrosis, follicular 
INKers, naked hair shafts, follicular asymmetry and PDIRS. There was loss of sebaceous 
glands in most of our cases and absent normal follicular units in all. In contrast to the 
literature, no vacuolization of the ORS , or epidermal involvement was noted. There was 
no parakeratosis, hyperkeratosis, hypergranulosis or follicular plugging. Dilation of 
eccrine ducts in 60% of LPP cases was observed, which has not been reported. In contrast 
to intrafollicular lymphocytes in 60% of our patients with LPP , the presence of 
intrafollicular lymphocytes has not been reported in LPP. 
Histopathologic findings of CCCA and LPP are compared in Table 10. A 
previous study in 2005 suggested that lymphocytic alopecias are not distinguishable by 
histopathologic findings.18 An attempt was made to see if distinctive findings can be 
identified which maybe specific for either CCCA or LPP. Only patients who were 
evaluated and had a biopsy by a single clinician, Dr. Goldberg, in order to ensure the 
clinical diagnoses of CCCA and LPP were included. The site of biopsy in all cases was 
chosen from the most active area of the affected scalp. 
Nineteen cases of CCCA and 5 cases of LPP were evaluated. The limited number 
of subjects in this study was due to the fact that many cases presented with late or end 
stage disease, and that early in the study period slides were routinely cut vertically rather 
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than horizontally (as required for quantification). Among all the histopathologic features 
collected, there were four that showed a statistically significant difference between the 
LPP and CCCA groups (Table 11). These were the presence of normal follicular units, 
complete loss of sebaceous glands, dilation of eccrine ducts and perifollicular 
inflammation. The presence of normal follicular units unaffected by the scarring process 
suggested the diagnosis of CCCA. Normal follicular units in 58% of CCCA cases and in 
none of LPP cases. The morphologically affected follicular units exhibited diminished or 
absent sebaceous glands and a decreased number of follicles per unit. 
Similarly, CCCA exhibited less loss of sebaceous glands (complete loss .of 
sebaceous glands was found in 10% of CCCA cases vs. 60% of LPP cases). The 
remaining cases of CCCA had only partial or no loss of sebaceous glands. The finding 
that in CCCA some follicular units are spared and sebaceous glands are often retained 
suggests that pathogenic pathways that lead to scarring via loss of sebaceous glands, such 
as the PP AR gamma pathway, may not be as important in CCCA as in LPP. While 
sparing of some hair follicles has also been reported in LPP / 1 the authors did not 
comment on the presence or absence of sebaceous glands. 
This study is the first to describe dilation of eccrine ducts in LPP. Dilation of 
eccrine ducts was present in the reticular dermis at the level of the inferior hair follicle in 
60% of LPP cases, without significant association of the presence of dilation of eccrine 
ducts and degree of inflammation or duration of disease. The finding of dilated eccrine 
ducts has been previously reported in CCCA, although it appeared to play no role in the 
etiology of the hair loss .75• 76 In 2012, Miteva and Tosti76 found dilated syringoma-like 
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eccnne ducts in over half of their CCCA cases and reported it to be a clue to the 
diagnosis. In contrast, the dilation of eccrine ducts was found in 60% of LPP cases and 
10% of CCCA cases in this study. 
The role of dilation of eccrine ducts in the pathogenesis of CCCA is unknown. It 
may represent a reactive process, similar to that which has been reported in a variety of 
benign neoplasms, malignant neoplasms, and non-scarring alopecia, including patterned 
hair loss77 and alopecia areata.78 In patterned alopecia and alopecia areata, eccrine ductal 
proliferation was found as a reactive process in the reticular dermis along with 
miniaturized follicles and telogen follicles. These ductal structures varied in size and 
degree of cystic dilation?7• 78 
Perifollicular inflammation at the level between the infundibulum and isthmus, 
with sparing of the lower follicle, has been described in both LPP and CCCA. However, 
the degree of inflammation in both conditions has not been compared. In this study, 
perifollicular inflammation was found to be more in intensity in LPP in comparison to 
CCCA. Moderate to severe perifollicular inflammation was found in 60% of LPP cases, 
whereas 90% of CCCA cases showed either mild or no perifollicular inflammation. The 
difference of degree of perifollicular inflammation may be the result of the difference in 
duration of disease between both groups, 3.8 years in LPP cases and 7 .4 years in CCCA 
cases. In the author's opinion, this difference in perifollicular inflammation reflects the 
clinical presentation of both diseases; evident perifollicular erythema in active lesions of 
LPP and subtler perifollicular erythema in CCCA. The perifollicular inflammation in 
lymphocytic scarring alopecias is a cell-mediated immune reaction to an unknown but 
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specific follicular antigen .35 The antigens that cause both diseases may be different, 
explaining the difference in perifollicular inflammation. 
In addition to the abovementioned features, there were histologic findings that 
differed between CCCA and LPP but did not reach statistical significance. These findings 
included the absence of vellus follicles , the presence of naked hair shafts, presence of 
follicular INK.ers and intrafollicular lymphocytes, which favored the diagnosis of LPP, 
while the presence of plasma cells and mucin, which favored the diagnosis of CCCA. In 
CCCA, there is a marked reduction of terminal hair follicles with some persistence of 
vellus hair follicles .49• 71 • 79 In LPP, Tan don et al.20 described a reduction of terminal hair 
follicles and disappearance of vellus follicles. However, in this study marked reduction of 
terminal and vellus follicles was observed in both CCCA and LPP. However, the absence 
of vellus follicles was found more often in LPP supporting the findings reported by 
Tandon et al. This suggests that in LPP the putative antigen that induces the 
inflammatory process leading to permanent follicular destruction is present not only in 
the terminal follicle but in the vellus follicle as well. 
Naked hair shafts are remnants of destroyed hair follicles that are often found in 
fibrotic streamers , usually surrounded by giant cells forming foreign body granulomas. 
Naked hair shafts have been described in many types of scarring alopecia including 
CCCA48 •80 and LPP57 . Miteva and Tosti described them in most cases of CCCA?6 At the 
isthmus level, naked hair shafts were seen in 60% of LPP cases and 16% of CCCA cases 
in this study (n.s.). The percentage of CCCA cases with naked hair shafts in this series 
was lower than that reported in the literature, suggesting that this finding might not be 
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specific to CCCA. The absence of naked hair shafts in our CCCA cases might be due to 
the late stage of disease, as naked hair shafts may eventually degenerate and be replaced 
by fibrotic scars. However, cases with less than three follicles were excluded in this 
study. 
Follicular INKers have been described in LPP in association with lichenoid 
lymphocytic infiltration at the level of the follicular infundibulum and isthmus.20 • 79• 81 In 
CCCA, in contrast, they were not described as a diagnostic finding.49 Follicular INKers 
were found in all LPP cases and in 50% of CCCA cases at both the isthmus and the level 
of the inferior follicle. There was no statistical significance between this finding in 
CCCA and LPP. Furthermore, the presence of follicular INKers correlated with the 
degree of perifollicular inflammation; follicular INKers were found more in cases with 
moderate to severe perifollicular erythema compared to cases with absent or mild 
perifollicular erythema. Thus, follicular INKers appear to reflect the degree of 
perifollicular inflammation and may not be independent distinguishing feature between 
LPP and CCCA. 
Intrafollicular lymphocytes were not specifically described as findings in either 
CCCA or LPP _zo, 49• 73 The finding of iritrafollicular lymphocytes in 60% of LPP cases and 
37% of CCCA cases in this study represents another histologic finding in lymphocytic 
scarring alopecia. Surprisingly, the presence of intrafollicular lymphocytes did not 
parallel the degree of follicular inflammation. Intrafollicular lymphocytes were found in 
41% of all CCCA and LPP cases with absent or mild perifollicular inflammation, and in 
43% of all CCCA and LPP cases with moderate to marked perifollicular inflammation. It 
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may be that any amount of perifollicular inflammation is sufficient to enter the epidermis, 
or alternatively that the amount of perifollicular inflammation is dynamic; cases with 
mild inflammation may have had heavier inflammation at some point in time. This 
remains to be elucidated. 
Plasma cells have been described as a histologic feature in CCCA,11 • 20 • 57 
folliculitis decalvans,u alopecia syphilitica82 and erosive pustular dermatosis of the 
scalp,83 but not as often in LPP.84 In CCCA, perifollicular plasma cells were found along 
with lymphocytes at levels between the infundibulum and isthmus.u. 48• 57 Plasma cells 
represent a chronic inflammatory process, as they are found in later stages of CCCA and 
folliculitis decalvans. 11 In this study plasma cells were found at the isthmus level in 68% 
of CCCA cases and 20% of LPP cases. This finding may reflect the longer duration of 
disease in CCCA cases compared to LPP. 
Mucinous perifollicular fibrosis has been described in the upper dermis in LPP, 
but not in CCCA?0· 25 In LPP, perifollicular mucin was found in the upper dermis in up to 
1/3 of the cases but was absent in the interfollicular dermis?0 It was described in chronic 
lesions together with perifollicular fibrosis.20 ' 25 Perifollicular mucin was observed in 20% 
of LPP cases and 68% of CCCA cases at the level of the isthmus. Mucin was absent from 
the interfollicular dermis in all cases. The percentage of cases with perifollicular mucin in 
our LPP cases was not different from those reported in the abovementioned publication?0 
In addition, the finding of perifollicular mucin in many of our CCCA cases suggests that 
this is not a distinguishing feature between the two diseases. 
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Many of our histologic findings were previously described in both LPP and 
CCCA and did not distinguish the two diseases. These include the presence of fibrous 
tracts at the isthmus and inferior levels, follicular asymmetry, the presence of fused 
follicles and perifollicular fibrosis . 
Fibrotic tracts lacking elastic fibers were described in scarring alopecia.72 Variable 
numbers of fibrotic tracts were found in our cases, with no difference between LPP and 
CCCA. The fibrotic tracts were the result of permanent follicular damage destroying 
follicular stem cells at the bulge region. There was no linear association of the number of 
fibrotic tracts and the number of remaining hair follicles. This random number of the 
fibrotic tracts raise the hypothesis that not every destroyed hair follicle results in a tract, 
and that after a certain period of time it is possible that fibrotic tracts are no longer 
evident with H&E staining. 
Follicular asymmetry has been described in scarring alopecia , non-scarring 
alopecia, and in normal scalp of African American patients.76 In CCCA, the hair shaft 
occupies an asymmetric position within both terminal and vellus follicles with an 
asymmetric ORS .76 The hair shaft may then migrate toward one side and ultimately 
perforate through the ORS .51 ' 80 Two or three follicular infundibula often fuse and form 
compound structures .76 In LPP, Headington described eccentric hair shaft placement 
within the follicle and fusion of damaged infundibula creating a compound follicle.57 •85 
Follicular asymmetry along with compound follicles was observed in both CCCA and 
LPP. There was no difference in the level or character of compound follicles among the 
two diagnoses. These results support the notion that follicular asymmetry and follicular 
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fusion are histologic findings in lymphocytic scarring alopecia in general, and are not the 
distinguishing findings between LPP and CCCA. 
Perifollicular fibrosis is a feature of scarring alopecia. In CCCA, concentric 
perifollicular lamellar fibrosis has been found at the level of the isthmus.48•51•57 •85 In LPP, 
concentric lamellar fibrosis was also described along the follicle at the level of 
infundibulum and isthmus?0 • 57 Neither study commented on its degree. Perifollicular 
fibrosis was noted in the majority of our cases- all LPP cases and 90% of CCCA cases, 
at both the isthmus and the level of the inferior follicle (n.s.). There was no correlation 
between the degree of perifollicular fibrosis and the degree of perifollicular 
inflammation. The presence of perifollicular fibrosis was a diagnostic finding of scarring 
alopecia, but the presence and degree of fibrosis did not distinguish between CCCA and 
LPP. 
No epidermal involvement was found in any cases of LPP or CCCA. These 
findings differed from those of Tandon et al.20 and Annessi et al.,81 who described 
interfollicular lichenoid infiltration along with hypergranulosis, vacuolar changes and 
INKers in some LPP cases. No epidermal thinning was observed in CCCA cases, which 
is different from the epithelial atrophy described by Lopresti et al.50 Although fewer 
cases were available to compare, epidermal involvement was not a helpful distinguishing 
feature between LPP and CCCA. This may be due to the lower number of cases, as 
compared to Tandon et al or Annessi et al. 
The main limitation of this study was the small sample size. Cicatricial alopecias 
are rare diseases , and scalp biopsies need to be cut horizontally for adequate 
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quantification of findings. This limited number of cases hindered the finding of statistical 
significance for many of the different histologic features of CCCA and LPP. Another 
' 
limitation of this study was the fact that it was retrospective in nature. Some data in the 
medical record were missing or briefly described. A prospective study that provides 
systematic and standardized data collection is needed to confirm our results. 
Study 1. Conclusion 
CCCA and LPP are lymphocytic scarring alopecia those share many overlapping 
findings histologically. Clinico-pathological correlation is always required for the definite 
diagnosis. This study found that the findings of unaffected follicular units, retained 
sebaceous glands and mild perifollicular inflammation favors a diagnosis of CCCA, and 
dilated eccrine glands and heavy perifollicular inflammation favor LPP. 
42 
STUDY 2. Direct immunofluorescent staining in the distinction between lichen 
planopilaris and central centrifugal cicatricial alopecia 
Study 2. Materials and Methods 
A prospective, cross-sectional data analytic study to identify immunofluorescent 
and immunohistochemical features that distinguish between LPP and CCCA was 
designed. The study was approved by the Institutional Review Board (IRB) at the Boston 
University Medical Center under protocol number H-31220. 
Patients being evaluated by Dr. Goldberg who had suspected lymphocytic 
scarring alopecia and required a biopsy were invited to participate. After informed 
consent was obtained, the patients underwent two biopsies, one for standard diagnostic 
testing and one for research purposes. Patients being evaluated by Dr. Goldberg who 
already had a biopsy for standard diagnostic testing were invited to participate by 
undergoing a biopsy for research purposes (Figure 9). Each research biopsy was 
transferred to the Skin Pathology Laboratory in Michel ' s transport medium and was 
vertically cut in half, with half frozen for immunofluorescent staining for Study 2, and 
half put in formalin for immunoperoxidase staining for Study 3 (Figure 10). 
Each half specimen for Study 2 was embedded in cryo-embedding media and 
stored at -80 oc until ready for sectioning. They were later cut in four micron cryostat 
sections and rinsed in PBS. Two hundred ul of immunofluorescent antibodies to IgG, 
IgM, IgA, C3, and fibrinogen were applied, one per slide, for 30 minutes, rinsed with 
buffer, mounted with fluorescent mounting medium, coverslipped and stored at 2-8 oc in 
the dark. One section was stained with H&E for anatomical comparison. All antibodies 
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were run with positive controls, provided by the Skin Pathology Laboratory. 
All direct immunofluorescent stains were interpreted by both Dr. Rattanasirivilai 
and Dr. Goldberg. The immunofluorescent findings were reported as either positive or 
negative . Positive findings were subdivided as to the pattern of the staining . The data 
collection form can be found in the Appendix 2. 
Study 2. Inclusion and Exclusion Criteria 
Patients who were being evaluated by Dr. Goldberg for standard clinical care who 
had suspected lymphocytic scarring alopecia were invited to participate. Both patients 
who required a biopsy for diagnosis and those who already had a biopsy interpreted as 
lymphocytic scarring alopecia were eligible to participate. Exclusion criteria included 
those patients whose biopsies did not show scarring alopecia. 
Study 2. Sample Size 
Two patients were informed consent and agreed to undergo a research biopsy in 
addition to their diagnostic biopsy. Nine patients, who had already been biopsied for 
diagnostic purposes, were informed consent and agreed to undergo a research biopsy. We 
did not exclude any cases from the study. Total of eleven patients participated in this 
study. 
Study 2. Data analysis 
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Statistical analysis was performed using R, Statistical Software, version 2.14.1 
(2011-12-22) and AnalystSoft Inc., StatPlus:Mac, version 2009. Qualitative variables 
were calculated in percentages and Fisher exact test was used for intergroup comparison. 
A p-value of less than 0.05 was considered statistically significant. 
Study 2. Results 
Four patients with CCCA and seven with LPP consented to participate in the 
study. Once the data was collected, medical records were reviewed. Relevant 
demographic data is shown in Table 12. Most patients were female, with the exception of 
two male patients with LPP. All CCCA patients were Mrican American, while all LPP 
patients were Caucasian. The mean age of patients in the LPP group was higher than in 
the CCCA group, 54.3 and 40.3 years old, respectively. The mean duration of disease 
prior to the biopsy in the CCCA group was highly variable from 2 to 20 years, with a 
mean duration of 7 years. In the LPP group, the duration of disease prior to biopsy ranged 
from 1 to 7 years, with a mean duration of 3.2 years. 
Positive DIF findings were found in 3 of 11 cases, two in LPP (cases LGP-004 
and LGP-008), and one in CCCA (LGP-007). The positive reactants were IgG in two 
cases, C3 in two cases and fibrinogen in one case . The patterns of deposition were varied, 
including linear, shaggy and granular. The location of deposition varied as well, from the 
isthmus to the deep perifollicular level (Table 13). Result of DIF along with clinical 
information including diagnosis, duration of disease, degree of perifollicular erythema, 
degree of perifollicular inflammation and previous treatments is shown in Table 14. 
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There was no appreciable difference in duration of disease between the positive and 
negative cases, although the positive cases tended to have more inflammation and were 
not previously treated with either intralesional steroid injection or systemic treatment. 
Of the seven patients with LPP, two had a positive DIF, cases LGP-004 and LGP-
008 (Table 15). In case LGP-004, linear, shaggy deposition of IgG at the perifollicular 
basement membrane at the inferior portion of hair follicle were noted. There was no 
positive staining of cytoid bodies or of the interfollicular dermis. All the other stains were 
negative, as shown in Figure 11. 
Shaggy/granular deposition of lgG and C3 at the perifollicular basement 
membrane of the hair follicle at the isthmus level was found in case LGP-008, as shown 
in Figure 12. There was no positive staining of cytoid bodies or of the interfollicular 
dermis, and other stains were negative . 
Of the four patients with CCCA, one (LGP-007) had a positive DIF (Table 16). In 
case LGP-007 , shaggy deposition of C3 at the perifollicular basement membrane of the 
hair follicle at the infundibulum and isthmus levels was observed, as shown in Figure 13. 
There was no positive staining of cytoid bodies or of the interfollicular dermis. Other 
stains were negative. 
Study 2. Discussion 
Previous studies on DIF findings in LPP reported highly variable results. In 1992, 
Ioannides and Bystryn67 found immunoglobulins at the DEJ of the follicular epithelium 
without interfollicular deposits or deposition on cytoid bodies in all 7 LPP cases studied. 
46 
These immunoglobulins consisted solely of IgG or IgA, or a combination of IgG and IgA. 
Linear deposition of a combination of IgG, IgM and fibrin at the BMZ were sometimes 
present (Table 17). The details of where along the hair follicle the immunoreactants were 
located were not reported. Their DIF results were different from those reported in lichen 
planus (Table 18). While LPP and LP are commonly thought to share the same etiology, 
this difference raised questions about the relationship between LPP and LP. 
During the same year, Mehregan et al.Z1 described deposits of immunoglobulin at 
the DEJ of follicular epithelium in some cases of LPP, and interfollicular deposits and 
cytoid body deposition in many, similar to the findings in LP (Table 18). Further details 
of the anatomical location of the positive findings in follicular epithelium were not given. 
From their findings, they supported the idea of LPP and LP sharing the same etiology but 
manifest on different areas of the body. In 2003, Chieregato et al.25 studied DIF findings 
in 30 cases of LPP and found linear fibrinogen deposition and positive cytoid bodies with 
lgM deposition up to 43% of cases at dermoepidermal junction, and non-specific 
deposition in the rest (Table 17) 86-88 • There were no details provided on the non-specific 
cases. Their results were similar to Mehregan et al. 21 None of these studies discussed 
contributing factors to positive or negative DIF findings, or which antigens might be 
being targeted. 
The sample size of this study was limited by the number of patients who 
consented to participate. A total of 11 patients consented to participate, 4 who were found 
to have CCCA, and 7 LPP. Our DIF results were different from those previously 
reported. Only a few cases with strongly positive DIF were observed in both the LPP and 
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the CCCA groups. Only two of seven cases of LPP had positive DIF. Both had IgG 
staining of the perifollicular BMZ in combination with a second reactant (fibrinogen in 
LGP-004 and C3 in LGP-008). However, the pattern and location of deposition of IgG in 
the cases was different; one was linear/shaggy at the inferior portion of the follicle, 
whereas the other had shaggy/granular deposition at the isthmus portion of the follicle. 
Only one of four CCCA cases had positive DIF. Unlike in LPP there was no IgG staining. 
Positive C3 staining in a shaggy/granular pattern at the isthmus level were observed. 
None of the positive cases of both diseases exhibited positive staining of cytoid bodies or 
of the interfollicular basement membrane. There was no consistency in the antibody 
deposited or the pattern of the deposition. These findings in LPP were similar to those of 
Ioannides and Bystryn, with lgG deposits at the follicular epithelium without lgG 
interfollicular or colloid body staining. These cases did not exhibit a specific anatomic 
follicular location of immune reactant deposition. 
Positive DIF was found to be associated with moderate perifollicular 
inflammation, both from a clinical standpoint and what was found on H&E staining. The 
association of a positive DIF and moderate perifollicular inflammation is statistically 
significant, p=0.006. This association has not been previously described. While the cause 
is unknown, the patients with moderate inflammation may represent those with active 
disease; hence immunoglobulin deposition was found. In addition, all of the positive 
cases had not received treatment with intralesional steroid injection or systemic agents. 
These treatments might reduce the degree of inflammation and thus deposition of 
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immunoglobulin. Of note, the association of previous treatment and positive DIF was not 
statistically significant. 
The duration of the disease in the positive cases was 2, 2.5 and 3 years. There was 
no appreciable difference in duration of disease between the positive and negative cases. 
None of the cases with duration of disease longer than 3 years had positive DIF staining, 
although some cases with duration of disease 1 or 2 years with mild inflammation also 
had a negative DIF. This shows that duration of disease may not be related to disease 
activity, and that duration of disease activity differs from case to case. Those cases with 
negative findings could be due to low disease activity from partial treatment, long 
standing disease prior to the biopsy, or inflammation that has subsided due to the natural 
course of the disease. With the limited number of positive cases, no pattern of association 
between the type of the immunoglobulin deposit and duration of disease was observed. 
Study 2. Conclusion 
There are no DIF findings that can reliably distinguish LPP from CCCA. The 
presence of a positive DIF is correlated with the amount of inflammation (p=0 .006). It is 
possible that long duration of disease, disease activity, and treatment of disease affect the 
sensitivity of DIF. Future studies should be limited to patients with new, untreated and 
active disease. 
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STUDY 3. The immunohistochemical distinction between lichen planopilaris and 
central centrifugal cicatricial alopecia 
Study 3. Materials and Methods 
Immunohistochemical staining was used to compare T -cell subsets and 
Langerhans cells in LPP and CCCA. A prospective, cross-sectional data analytic study 
was designed to identify both immunohistochemical features that distinguish between 
LPP and CCCA. The details of patient selection can be found in the Material and 
Methods of Study 2. 
After the biopsy was obtained, the tissue was transferred to the Skin Pathology 
Laboratory in Michel's transport medium and was vertically cut in half, with half frozen 
for immunofluorescent staining for Study 2, and half put in formalin for 
immunoperoxidase staining for Study 3. Each half of vertically cut specimen for Study 3 
was fixed in formalin, embedded in paraffin , cut vertically, and stained for the following: 
CD3, CD4, CD8, CDla, CCR6, FoxP3 and H&E. Details can be found in the Appendix 
3. All immunohistochemical stains were run with a positive control (tonsil), provided by 
the Skin Pathology Laboratory. Details of the antibodies used can be found in the 
Appendix 4. 
Data interpretation was done by both Dr. Rattanasirivilai and Dr. Goldberg, who 
were blinded from diagnosis at the time of data collection. For each case , the area with 
the greatest amount of inflammation on the H&E slide were chosen and photographed at 
200x (Olympus DP26 Digital Camera). This same area was identified for each antibody 
and photographed. The number of positive cells in the photographs were counted 
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manually for each antibody. A positive cell was considered when greater than or equal to 
half of the cell was present in the section. 
Results were reported as the number of each antibody positive cells per 
photographed 200x field, the percentage of CD4, CD8, CCR6 and FoxP3 positive cells 
compared to CD3 positive cells, the ratio of CD4: CDS positive cells, and the ratio of 
CD1a:CD3 positive cells. Cases were then unblinded and grouped by diagnosis into LPP 
and CCCA. The LPP group was also further subdivided by duration of disease. Medical 
records were reviewed for relevant demographic and clinical data, including age, sex, 
duration of disease and previous treatment. 
For each group, the mean number of positive cells for each antibody, the mean 
percentages of CD4, CD8, CCR6 and FoxP3 (which mark T-helper cells, cytotoxic T-
cells, Th17 cells and regulatory T cells, respectively), and the mean ratios of CD4:CD8 
and CD1a:CD3 were calculated . In order to determine if there was a difference in the 
degree of inflammation in different stages of disease, the LPP group was divided by 
duration into greater or less than 1 year. 
Study 3. Inclusion and Exclusion Criteria 
Patients who were being evaluated by Dr. Goldberg for standard clinical care and 
who suspected to have lymphocytic scarring alopecia were invited to participate. Both 
patients who required a biopsy for diagnosis and those who already had a biopsy 
interpreted as lymphocytic scarring alopecia were eligible to participate. Exclusion 
criteria included those patients whose biopsies did not show scarring alopecia. 
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Study 3. Sample Size 
Two patients agreed to undergo a research biopsy in addition to their diagnostic 
biopsy. Nine patients who had already been biopsied, and had a confirmed diagnosis of 
LPP or CCCA, agreed to undergo a research biopsy. One 4-mm punch biopsy was 
obtained from each case. 
Study 3. Data analysis 
Statistical analysis was performed using R, Statistical Software, version 2.14.1 
(2011-12-22) and AnalystSoft Inc., StatPlus: Mac, version 2009. Quantitative variables 
were calculated in means and range of minimum to maximum, and T -test was used for 
intergroup comparison of means, percentages and ratios. Qualitative variables were 
calculated in percentages and Fisher exact test was used for intergroup comparison. A p-
value of less than 0.05 was considered statistically significant. 
Study 3. Results 
Patients recruited in this study were identical to the patients in Study 2 (see page 
47). Examples of the chosen area with the most inflammation and the photographs of the 
immunohistochemical stains are shown in Figure 14. The chosen area for each case was 
either perifollicular or perivascular, superficially at the level of the isthmus. The number 
of positive cells for all antibodies is shown in Table 21. 
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The number of CD3 positive cells was highly variable, ranging from 9-340 
cells/200x field. There were three cases, LGP-002, LGP-005 and LGP-010 , with less 
than 50 CD3 positive cells/200x field. These were cases that either had longer duration of 
disease (LGP-005, 7 years and LGP-010, 20 years) or had less perifollicular erythema 
clinically (LGP-002). The number of CD3 positive cells was higher than the other 
antibodies studied. There were 5 cases with a higher number of CD4 positive cells 
compared to CD8, 5 cases with a higher number of CD8 positive cells compared to CD4, 
and one case with equal numbers of CD4 and CD8 positive cells. The number of CCR6 
positive cells was less than the number of both CD4 and CDS cells in 6 cases, greater 
than the number of CD4 positive cells in 3, and greater than the number of CDS positive 
cells in 2. The presence of FoxP3 positive cells was very limited, with a mean of 2 cells. 
CD 1 a positive cells were counted from the chosen area in the dermis, and not from the 
follicular epithelium or epidermis. The number of CD1a positive cells ranged from 1-27 
cells/200x field with mean of 7 cells. 
Tables 22 and 23 show the number of positive cells grouped by diagnosis. The 
comparison of the mean number of CD3, CD4, CDS, CCR6, FoxP3 and CD1a positive 
cells in LPP and CCCA is shown in Figure 15. The LPP group had slightly higher means 
of CD3, CD4, CD8 and CCR6 positive cells, although this was not statistically 
significant. The mean numbers of FoxP3 and CD1a positive cells in both groups was 
similar. 
The percentages of the different T -cell subsets compared to the total number of 
CD3 cells and the ratios of CD4 positive to CD8 positive cells and CD1a positive to CD3 
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positive cells for LPP is shown in Table 24. CD4 positive cells outnumbered CD8 
positive cells in 3 cases, and CD8 outnumbered CD4 in 4. One case exhibited equal 
numbers of CD3 positive and CD8 positive cells. In all but three cases, there were less 
CCR6 positive cells than CD4 or CD8 . FoxP3 positive cells were scarce except for in one 
case. The CD4:CD8 ratios were highly variable. The ratio of CD1a to CD3 cells was low 
in all cases. There was no statistical significance in these differences. 
The percentages of the different T -cell subsets compared to the total number of 
CD3 cells and the ratios of CD4 positive to CD8 positive cells and CDla positive to CD3 
positive cells for CCCA is shown in Table 25. CD4 positive cells outnumbered CD8 
positive cells in 2 cases, and CD8 outnumbered CD4 in 2. There were less CCR6 positive 
cells than CD4 or CD8 in all 4 cases. FoxP3 positive cells were scarce in all cases. The 
CD4:CD8 ratios were highly variable. The ratio of CDla to CD3 cells was low in all 
cases . There was no statistical significance in these differences. 
The means ratios of CD4 to CD8 positive cells and CD1a to CD3 positive cells in 
LPP and CCCA are shown in Figure 16. The mean CD4 to CD8 ratio in the CCCA group 
was almost twice that of the LPP group, shown in Figure 17. The mean CD1a to CD3 
ratio was about the same in both groups. 
The number of positive T-cell subsets and CD1a positive cells for LPP with 
duration of disease less than 1 year and greater than 1 year are shown in Tables 26 and 
26, respectively. 
Percentages of CD4, CD8, CCR6 and FoxP3 positive cells compared to the 
number of CD3 positive cells and the ratios of CD4 to CD8 positive cells and CD1a to 
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CD3 positive cells in LPP with duration of disease less than 1 year and greater than 1 
year are shown in Tables 27 and 28, respectively, and compared in Figure 12. In the two 
cases of LPP with duration of disease less than 1 year, the percentage of CD8 positive 
cells compared to CD3 positive cells was higher than the CD4 percentage. 
The percentages of CD4, CD8, CCR6 and FoxP3 positive cells compared to the 
number of CD3 positive cells in both LPP with duration of disease less than 1 year, 
greater than one year, and CCCA, are shown in Figure 18. The percentage of CD4 in LPP 
with duration of disease less than 1 year is lower than other groups. The mean percentage 
of CD8 in both groups of LPP was higher in comparison to CCCA. However, this 
difference was not statistically significant. 
The mean CD4:CD8 ratios in each group are shown in Figure 19. The mean 
CD4:CD8 ratios in LPP with duration of disease less than 1 year is lower than in the 
other groups, and it increased in LPP with duration of disease over 1 year, approaching 
the CCCA group and what is found in the normal hair follicle. 
The mean CD1a:CD3 ratio in each group is shown in Figure 20. The CD1a:CD3 
in LPP with duration of less than 1 year is almost twice that of LPP with duration over 1 
year and CCCA. There was no statistical significance. 
Study 3. Discussion 
LPP and CCCA are scarring alopecias that manifest with lymphocytic 
perifollicular infiltration. The immunopathogenesis of the inflammatory cells in these 
diseases has not been well studied. It is possible that these lymphocytes are the primary 
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mediators of follicular destruction via a cell-mediated immune reaction to an endogenous 
or exogenous follicular antigen. 89-9 1 
In cell-mediated immune reactions in general, Langerhans cells play a role as 
antigen-presenting cells that present an as yet unknown antigen to CD4 positive T-
lymphocytes. Following antigen recognition, CD8 positive cells are activated and 
undergo clonal expansion. These activated lymphocytes release cytokines and 
chemokines, such as interleukin (IL)-2, IL-4, IL-10, interferon-gamma, tumor necrosis 
factor alpha and transforming growth factor beta. These cytokines attract and regulate the 
trafficking of more lymphocytes to the affected area. As a result, the inflammatory 
process induces keratinocyte apoptosis. If this cell-mediated immune process at the hair 
follicle affects the bulge area where multipotent stem cells reside, permanent follicular 
destruction and scarring alopecia may be the consequence.89-91 
Previous studies34 ' 92 evaluating the cellular components of the inflammation in 
LPP have supported the theory of a cell-mediated immune process. One study by Mobini 
in 2005 showed an increase in CD8 T lymphocytes compared to CD4.34 They found a 
reverse in the CD4:CD8 ratio of 1:1-2, whereas in the normal hair follicle it is 2:1.93 They 
also found a decrease in the number of Langerhans cells in the bulge region in affected, 
as compared to normal follicles ?4 
The work of Hutchens et al.92 also supported a cytotoxic inflammatory process in 
LPP by comparing Langerhans cell concentrations in LPP and traction alopecia. There 
was a significantly higher ratio of Langerhans cells to T lymphocytes in LPP compared to 
what was found in traction alopecia (1.3 vs 0 .6). This demonstrated the usefulness of the 
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ratio of CDla positive cells to CD3 positives cells and suggested separate inflammatory 
pathways for LPP and traction alopecia, both of which result in scarring alopecia. In LPP, 
Langerhans cell triggered a cytotoxic inflammatory process and destroyed the hair 
follicle including the bulge region, home to multipotent stem cells, resulting in permanent 
hair loss. In traction alopecia, less evident inflammatory cells despite the presence of 
Langerhans cells suggested a different pathogenesis. It has been suggested that the helical 
shape of the hair shaft in African Americans is more vulnerable to traumatic injury, and 
likely to be the cause of chronic follicular damage in traction alopecia leading to 
permanent hair loss.76 
A New Zealand black mouse model (NZB/KN) established for the study of 
chronic rheumatoid arthritis and systemic lupus erythematosus was found to also have 
autoimmune-induced scarring alopecia.94 These mice had normal hair morphogenesis and 
hair cycling in early life and developed progressive alopecia as they grew. The study of 
inflammatory cells around the hair follicles revealed increased number of CD3 , CD4 and 
CD8 positive cells around the bulge of hair follicles and blood vessels.94 This study 
supported the notion that perifollicular lymphocytic inflammation involving the hair 
bulge, and not an exogenous triggering antigen, contributes to lymphocytic scarring 
alopecia. 
In this study, variable numbers of CD3, CD4 and CD8 positive cells in 
inflammatory areas were found in both conditions. When comparing between the CCCA 
group and the LPP group, the number and percentage of CD8 positive cells in the LPP 
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group was higher than in the CCCA group. There is no previously published data with 
which to compare these findings . 
In this study, the CD4:CD8 ratio in CCCA (2.15:1) was similar to what is found 
in the normal hair follicle (--2: 1) .93 On the contrary, the CD4:CD8 in LPP in this study 
was 1.25:1, suggesting that there may be a cytotoxic inflammatory process in this 
condition. This finding is consistent with previous data by Mobini.34 However, the 
difference of these ratios was not statistically significant. 
LPP cases were stratified by duration of disease and found a trend in the altered 
CD4:CD8 ratio. In early disease (duration <1 year), the CD4:CD8 was as low as 0.5, and 
it increased to 1.55 in cases with duration > 1 year. This finding has not been described in 
the literature and suggests a role of a cytotoxic inflammatory process in early disease. 
The inflammatory process remodels as the disease progresses, and the role of cytotoxic 
inflammation in later lesions was not as significant as in early lesions. This was 
suggested by the change in CD4:CD8 , which evolved toward what is found in normal 
hair follicles. 
The number of CD1a positive cells in the CCCA and LPP groups were not 
different, but the ratio of CD1a:CD3 in the LPP group was slightly higher. The 
CD1a:CD3 represents the role of Langerhans cell in lymphocytic scarring alopecia. This 
ratio in LPP was different from traction alopecia.92 In this study, the difference of 
CD1a:CD3 between LPP and CCCA was not statistically significant. 
When stratified by duration of disease, we found that the CD1a:CD3 in LPP with 
duration < 1 year (0 .14) was almost twice that of LPP with duration > 1 year (0 .08) and 
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CCCA (0 .07). These findings were consistent with data published by Hutchens et al.92 in 
2011 comparing CD1a:CD3 in LPP and traction alopecia, which suggested role of CD1a 
as antigen-presenting cells in LPP, especially in early disease. These findings are 
consistent with previous data by Pozdnyakova and Mahalingam showing the presence of 
CD1a cells in early stages of scarring alopecia.95 Of note, this latter study compared the 
findings among stages of disease but did not distinguish between different types of 
scarring alopecia. The number of cases was insufficient to stratify CCCA by duration of 
disease in this study. 
Recently, subtypes of CD4 positive cells were found to play a key role in T 
lymphocyte mediated inflammatory processes such as psoriasis. These cells include Th17 
positive lymphocytes and regulatory T lymphocytes (Tregs) .96-98 Th17 lymphocytes 
differentiate from naive CD4 positive cells and respond to certain extracellular pathogens 
and fungi. Th17 lymphocytes express CCR6, IL-23R, CXCR4, CD161 and multiple 
CD49 integrins and produce IL-17 and IL-17F .99 Other dermatoses with increased Th 17 
positive lymphocytes include atopic dermatitis, drug-induced hypersensitivity syndrome 
and acute generalized exanthematous pustulosis.100 ' 101 Increased Th17 lymphocytes and 
its cytokines are associated with alopecia areata and alopecia universalis.100 102 
CCR6, a marker of Th17 lymphocytes, is a transmembrane protein regulating 
migration and recruitment of T cells during inflammation and immunologic responses. 
We found CCR6 positive lymphocytes in both CCCA and LPP. This finding suggests a 
role of Th17 lymphocytes in lymphocytic scarring alopecia. The Th17 lymphocytes may 
regulate the migration and recruitment of other T cells in the follicular inflammatory 
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process, which subsequently results in follicular destruction and permanent hair loss. This 
finding is important, as the finding of Th17 lymphocytes in other dermatoses, such as 
psoriasis, has had therapeutic implications. Ustekinumab, a monoclonal antibody 
targeting Th 17 1 ymphocyte activators, IL-12 and IL-23, blocks Th 17 lymphocyte 
differentiation and amplification. Ustekinumab has been shown to significantly improve 
psoriasis.103 The finding of CCR6 in cicatricial alopecia is preliminary, and further studies 
are needed to confirm their presence and perhaps identify elevated levels of Th17 
cytokines. If confirmed, targeting of Th17 lymphocytes may be a promising strategy for a 
novel treatment of LPP and CCCA. 
Treg cells are a distinct, mature subpopulation of T lymphocytes derived from 
na"ive CD4 positive T lymphocytes. They account for 5-10% of the total CD4 positive T 
cell population. They are characterized by expression of the Forkhead family 
transcription factor 3 (FoxP3), which is a transcription factor crucial in Treg cells 
development and function. 104 Tregs serve to regulate the cutaneous immune response, 
maintain immune tolerance and control autoreactive T cells. Dysfunction of Tregs could 
significantly contribute to autoimmune disease susceptibility .105 An increased number of 
Tregs were found in psoriasis, but they had impaired function. 106 Other dermatoses with 
increased numbers of impaired Tregs include atopic derffiatitis and systemic lupus 
erythematosus.107 Tregs were found to be diminished in cutaneous lesions of thymoma-
associated autoimmune disorder .108 
In alopecia areata, Tregs play a significant role in immunopathogenesis as pro-
inflammatory cells.105 Prior studies found a decreased number of, and defective 
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function 102 of, Tregs in lesional skin of alopecia areata.109 Decreased numbers of Tregs 
and defective Treg function may contribute to a decreased threshold of autoreactive 
perifollicular inflammation and subsequent alteration of the follicular cycle. The function 
of Tregs in peripheral blood of alopecia areata patients has also found to be defective. 102' 
110 There have been no previous studies on the role of Tregs in scarring alopecia. 
The main purpose of this study was to establish any difference in Tregs between 
LPP and CCCA. The FoxP3 positive cells were similarly rare in patients with LPP and 
CCCA, and there was no significant difference between the groups. There was no 
difference of FoxP3:CD3 among the LPP and the CCCA groups. The limited number of 
Treg may decrease protection against an autoreactive inflammatory process such as 
lymphocytic scarring alopecia. This hypothesis remains to be elucidated. To establish the 
pathogenic role of Tregs in scarring alopecia, future studies should compare the number 
of Tregs, and the ratio of Tregs and Treg secretory cytokines such as IL-12, IFN-y and 
TNF-a in actively involved hair follicles vs. normal hair follicles. 
The major limitation of this study was the limited number of patients who 
consented to participate. This curtailed our ability to establish statistical significance. 
Moreover, some of our cases had limited inflammation, presumably either due to prior 
treatment or to the fact that they were biopsied at a late stage of disease. In addition, the 
inflammatory cells were counted from chosen 200x fields. These may not representative 
the disease process as a whole. Although biopsies were obtained from perceived active 
areas, one could argue that the site of the biopsy on the scalp poses a similar 
representation issue, as inflammation in scarring alopecia can be focal and is subject to 
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sampling error. Future studies on inflammation in cicatricial alopecia may be limited to 
untreated patients with new onset and active disease. 
Study 3. Conclusion 
No significantly distinctive T lymphocyte populations that could differentiate 
between CCCA and LPP were found. However, several differences between the two 
diseases were noted. LPP had higher numbers and percentages of CD8 positive cells 
compared to CCCA. The CD4:CD8 ratio increased with duration of disease, approaching 
proportions similar to those found in the normal hair follicle and CCCA. A higher 
CDla:CD3 in LPP compared to CCCA and a trend of decreased CD1a:CD3 over time, 
approaching the ratio found in CCCA was observed. Our data confirmed the presence of 
CD8 positive lymphocytes and Langerhans cell as antigen presenting cells in early LPP, 
suggesting a cytotoxic inflammatory process at this stage of the disease. The study of 
Th17 lymphocytes and Tregs in scarring alopecia was pioneered. Th17 lymphocytes may 
have a role in pathogenesis of both CCCA and LPP. Insufficient function of Tregs may 
also be contributing. 
In conclusion, there are histopathologic findings that help in the distinction 
between LPP and CCCA. The findings of unaffected follicular units, retained sebaceous 
glands and mild perifollicular inflammation favor a diagnosis of CCCA, and dilated 
eccrine glands and heavy perifollicular inflammation favor a diagnosis of LPP. There are 
no DIF findings that reliably distinguish LPP from CCCA, although presence of a 
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positive DIF has found to correlate with the amount of inflammation. Future studies 
should be limited to patients with new, untreated, active disease. There are no specific T 
lymphocyte populations that differentiate between CCCA and LPP. However, this study 
confirmed the presence of CD8 positive lymphocytes and Langerhans cell as antigen 
presenting cells in early LPP, suggesting a cytotoxic inflammatory process at this stage of 
the disease. This study also suggested possible role of Th17 lymphocytes and Tregs in 
both CCCA and LPP. Our findings set the stage for larger studies of patients with early , 
active disease to further elucidate the pathogenesis of LPP and CCCA and the histologic 
features that set them apart. The possible role of Th 17 lymphocytes raises the possibility 
of use of an anti-Th 17 medication such as U stekinumab as a novel treatment for LPP and 
CCCA. 
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Figure 1. Schematic representation of follicle development and hair cycle. Selected 
stages from 8 stages of the morphogenesis of hair follicles and follicular cycling (anagen, 
catagen and telogen) are shown , adapted from Paus and Cotsarelis6 . 
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Figure 2. Vellus follicle (A) and terminal follicle (B) share similar basic anatomy but 
with different size. Terminal hair is about 5 times larger than vellus hair, adapted from 
Knorr et al.111 
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Figure 3. Anagen hair anatomic reference sites. The entry of the sebaceous duct (upper 
arrow) divides the infundibulum above from the isthmus below, and the insertion of the 
erector pili muscle, also called bulge region (lower arrow) divides the isthmus above 
from the inferior follicle below (from Dermatopathology Interactive Atlas, 2001, by 
Bhawan, Sau and Byers, with permission from Dr. Jag Bhawan).112 
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Figure 4. (A) Cross section of an anagen hair follicle at an inferior level, showing 
concentric layers of hair follicle . Arrow shows the connective tissue sheath. Square 
frames area in (B). (B) Different layers of hair follicle from innermost to periphery 
depicted by arrows. The lowest arrow shows the hair matrix which will form the hair 
shaft. The middle arrow shows the inner root sheath (IRS), which consists of the IRS 
cuticle, Huxley's layer and Henley's layer. The highest arrow shows the outer root sheath 
(from Dermatopathology Interactive Atlas, 2001, by Bhawan, Sau, Byers, with 
permission from Dr. Jag Bhawan).112 
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Figure 5. Outer root sheath (ORS) at different portions. (A) Infundibulum portion. 
Notice the continuity of ORS and epidermis. (B) Isthmus portion. Notice trichilemmal 
keratinization (epithelium with no granular layer). Arrow shows the hair bulge, which 
contains multipotent stem cells. (C) Inferior portion. ORS continues downward to the hair 
bulb where it becomes paler and larger (from Dermatopathology Interactive Atlas, 2001, 
by Bhawan, Sau and Byers, with permission from Dr. Jag Bhawan). m 
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Figure 6. Vertical section of anagen hair bulb showing hair matrix. Notice the hair 
matrix is continuous with the newly formed hair shaft. The hair matrix is surrounding the 
dermal papilla in "ball and claw" configuration (from Dermatopathology Interactive 
Atlas, 2001, by Bhawan, Sau and Byers, with permission from Dr. Jag Bhawan). 112 
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Figure 7. Study 1 Sample size 
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Figure 8. Examples of follicles with mild asymmetry and marked asymmetry (from 
Dermatopathology Interactive Atlas, 2001, by Bhawan, Sau and Byers, with permission 
from Dr. Jag Bhawan).112 
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invited to participate . 
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Figure 9. Subject recruitment for Studies 2 and 3 
71 
Part I 
Vertical frozen sections were cut 
and stored at -!m Celcius 
Immunoltuorescent staining 
(lgG, IgA. lgM . CJ , fibrinogen) 
Data collection 
Each biopsy was 
CUI into 1 parts 
longitudi nail y 
Part 2 
Vertical paraffin sections wen~ cut 
Immunopcroxidase staining 
!CD3. CD-L CD8 . CD Ia . CCR6. FoxP.l ) 
Data collection 
Data analysis. compare findings with diagnosis from gold standard 
(from clinicopathologic correlation with H&E staining) 
Figure 10. Tissue processing for Studies 2 and 3 
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Figure 11. Positive DIF findings in case LGP-004. (A) Vertical section of an anagen 
hair follicle at the inferior portion, H&E stain, 200x; (B) Linear/shaggy IgG deposition at 
the perifollicular BMZ; (C) Negative IgM staining; (D) Negative lgA staining; (E) 
Negative C3 staining; (F) Shaggy fibrinogen deposition at the perifollicular BMZ 
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Figure 12. Positive DIF findings in case LGP-008. (A) Vertical section of an anagen 
hair follicle . The rectangle frames the area of positive lgG deposition, H&E stain, 200x; 
(B) Shaggy/granular IgG deposition at the perifollicular BMZ at the isthmus level; (C) 
Vertical section of an anagen hair follicle. The oval frames the area of positive C3 
deposition; (D) Shaggy/granular C3 deposition at the perifollicular BMZ at the isthmus 
level, 400x. 
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Figure 13. Positive DIF findings in case LGP-007. (A) Infundibulum/isthmus level. 
The rectangle and oval frame areas of C3 deposition. H&E stain, 200x; (B) Negative IgG 
staining; (C) Negative IgM staining; (D) Negative IgA staining; (E) Shaggy C3 
deposition at the perifollicular BMZ at the infundibulum level; (F) Shaggy C3 deposition 
at the perifollicular BMZ at the isthmus level. 
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Figure 14. Case LGP-007 immunoperoxidase photographs 
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Figure 15. Comparison of means of positive cells from photos of 
immunohistochemical stains. None of the differences between LPP and CCCA were 
statistically significant. 
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Figure 16. Comparison of mean percentages of positive cells from photos of 
immunohistochemical stains of LPP and CCCA. None of the differences between LPP 
and CCCA were statistically significant. 
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Figure 17. Comparison of ratios of positive cells from photos of 
immunohistochemical stains of LPP and CCCA. None of the differences between LPP 
and CCCA were statistically significant. 
79 
60% 
52% 
50% • LPP, <1yr • LPP, > 1 yr • CCCA 
40% 
30% 
20% 
10% 
0% 
CD4% CDB% CCR6% FoxP3% 
Figure 18. Comparison of means of percentage of positive cells from photos of 
immunohistochemical stains of LPP with duration less than 1 year, more than 1 
year, and CCCA. None of the differences between LPP and CCCA were statistically 
significant. 
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Figure 19. Comparison of the CD4:CD8 of photos of immunohistochemical stains in 
LPP with duration less than 1 year, more than 1 year, CCCA, and normal follicles. 
The difference between LPP and CCCA was statistically significant. 
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Figure 20. Comparison of the CD1a:CD3 in photos of immunoperoxidase stains of 
LPP with duration less than 1 year, more than 1 year, and CCCA. The difference 
between LPP and CCCA was statistically significant. 
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TABLES 
Table 1. Classification of primary cicatricial alopecia, modified from the summary of 
North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial 
Al . 17 opec1a . 
Inflammatory cells 
Lymphocytes 
Neutrophils 
Mixed 
Nonspecific or end stage 
Cicatricial alopecia 
Lichen planopilaris (LPP) 
Frontal fibrosing alopecia 
Graham Little syndrome 
Central centrifugal cicatricial alopecia (CCCA) 
Alopecia mucinosa 
Keratosis follicularis spinulosa decalvans 
Folliculitis decalvans 
Dissecting cellulitis/folliculitis 
(Perifolliculitis abscedens et suffodiens) 
Folliculitis (acne) keloidalis 
Folliculitis (acne) necrotica 
Erosive pustular dermatosis 
Pseudopelade of Brocq 
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Table 2. Demographic data of subjects in study 1 
Characteristics CCCA, n=19 LPP,n=5 
Sex 5 (100%) F 18 (94.7%) 
M 1 (5.3%) 0 
Ethnicity 
Arican-American 19 (100%) 2 (40%) 
Causasian 0 3 (60%) 
Hispanic 
Age at time of 2(10.5%) 0 biopsy<30 years 16 (84.2%) 4 (80%) 30-60 years 1 (5.3%) 1 (20%) 
>60 years 
Mean age, range 44.3 years (26-68) 49.4 years (33-64) 
Mean duration of 7.4 years (1-20) 3.8 years (1-10) disease, (range) 
Table 3. The number of follicles at the isthmus and the inferior follicle 
CCCA, n=19 LPP,n=5 p-value Mean (range) Mean (range) 
Isthmus 
Total number of follicles 10.8 (4-17) 12.4 (7-19) 0.49916 
Number of terminal 7.4 (3-16) 11.6 (7-19) 0.06129 follicles 
Number of vellus 3.15 (1-14) 1 (0-2) 0.1389 follicles, 
Inferior follicle 
Total number of follicles 7.35 (3-16) 11.4 (3-19) 0.0592 
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Table 4. The number of fibrous tracts at the isthmus and the inferior follicle 
CCCA, n=19 LPP,n=5 p-value Mean Mean 
Isthmus 
None 1 (5.3%) 0 
1-5 6 (31.6%) 3 (60%) 0 .75 
6-10 7 (36.8%) 1 (20%) 
>10 5 (26.3%) 1 (20%) 
Inferior follicle 
None 0 0 
1-5 4 (21 %) 2 (40%) 0 .81 
6-10 5 (26.3%) 1 (20%) 
>10 10 (52 .6%) 2 (40%) 
Table 5. Select histopathologic findings in CCCA and LPP 
Findings CCCA,n=19 LPP,n=5 p-value 
Epidermal involvement 
Present 0 0 0.9 
Absent 19 (100%) 5 (100%) 
Normal follicular units 
Present 11 (57.9%) 0 <0.05* 
Absent 8 (42.1 %) 5 (100%) 
Loss of sebaceous glands 
None or partial 17 (89%) 2 (40%) <0.05* 
Complete 2 (11 %) 3 (60%) 
Fused follicles, isthmus 
Present 10 (52.6%) 4 (80%) 0.36 
Absent 9 (47.4%) 1 (20%) 
Fused follicles, inferior 
Present 0 1 (20%) 0.36 
Absent 19 (100%) 4 (80%) 
PDIRS 
Present 14 (74%) 3 (60%) 0 .61 
Absent 5 (26%) 2 (40%) 
Dilation of eccrine glands 
Present 2 (10.5%) 3 (60%) <0.05* 
Absent 17 (89.5%) 2 (40%) 
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FINKERs, isthmus 6 (31.6%) Present 2 (40%) 0.9 
Absent 13 (68.4%) 3 (60%) 
FINKERs, inferior follicle 
Present 10 (52.6%) 5 (100%) 0.12 
Absent 9 (47 .4%) 0 (0%) 
Naked hair shafts, isthmus 3 (15.8%) 3 (60%) Present 0.08 
Absent 16 (84.2%) 2 (40%) 
Naked hair shafts, inferior 
Present 7 (36.8%) 3 (60%) 0.61 
Absent 12 (63.1 %) 2 (40%) 
Intrafollicular lymphocytes, isthmus 
Present 7 (36.8%) 3 (60%) 0.61 
Absent 12 (63.1%) 2 (40%) 
Intrafollicular lymphocytes, inferior 
Present 0 (0%) 0 (0%) 0.99 
Absent 19 (100%) 5 (100%) 
Plasma cells, isthmus 
Present 13 (68.4%) 1 (20%) 0.12 
Absent 6 (31.6%) 4 (80%) 
Plasma cells, inferior 
Present 4 (24%) 0 (0%) 0.54 
Absent 15 (76%) 5 (100%) 
Mucin, isthmus 
Present 13 (68.4%) 1 (20%) 0.54 
Absent 6 (31.6%) 4 (80%) 
Mucin, inferior 
Present 4 (24%) 0(0%) 0.54 
Absent 15 (76%) 5 (100%) 
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Table 6. Grade of follicular asymmetry at the isthmus and the inferior follicle 
Grade of follicular CCCA, n=19 LPP, n=5 p-value 
asymmetry 
Isthmus 
No asymmetry 1 (5.3%) 0 
Mild 15 (78.9%) 3 (60%) 0 .44 Moderate 1 (5.3%) 1 (20%) 
Marked 2 (10 .5%) 1 (20%) 
Inferior follicle 
No asymmetry 3 (15.9%) 0 
Mild 10 (53%) 3 (60%) 0.59 Moderate 5 (26.5%) 1 (20%) 
Marked 1 (5.3%) 1 (20%) 
Table 7. Grade of perifollicular fibrosis at the isthmus and inferior follicle 
Grade of CCCA, n=19 LPP, n=S p-value perifollicular fibrosis 
Isthmus 
None 2 (10.5%) 0 
Mild 7 (36.8%) 0 0.75 Moderate 7 (36.8%) 3 (60%) 
Severe 3 (15.7%) 2 (40%) 
Inferior follicle 
None 2 (10.5%) 0 
Mild 15 (79%) 5 (100%) 0.9 Moderate 0 0 
Severe 2 (10.5%) 0 
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Table 8. Grade of perifollicular inflammation at the isthmus and the inferior follicle 
Grade of 
perifollicular CCCA, n=19 LPP,n=S p-value 
inflammation 
Isthmus 
Mild or absent 17 (89.4%) 2 (40%) 0.04 Moderate or severe 2 (10.5%) 3 (60%) 
Inferior follicle 
Mild or absent 17 (89.4%) 4 (80%) 0.52 Moderate or severe 2 (10.5%) 1 (20%) 
Table 9. Grade of perivascular inflammation at the isthmus and the inferior follicle 
Grade of perivascular CCCA,n=19 LPP, n=S p-value inflammation 
Isthmus 
None 2 (10.5%) 1 (20%) 
Mild 13 (68.4%) 2 (40%) 0.57 
Moderate 4 (21.0%) 2 (40%) 
Inferior follicle 
None 12 (63.2%) 4 (80%) 
Mild 7 (36.8%) 1 (20%) 0.52 
Moderate 0 0 
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Table 10. Histopathologic findings in LPP versus CCCA 
Characters CCCA11, 19,48-50,71 LPPzo. 21. 2s, 34, s1. 79,81 
Markedly reduced of termina Marked reduced of both 
Number of hair follicles follicle, some vellus hair terminal and vellus persist 
Parakeratosis, 
Epidermal keratin Absent hyperkeratosis, hypergranulosis and 
follicular plugging 
Absent in most cases, 
Absent some cases with lichenoid lnterfollicular epidermal Or epidermal atrophy infiltration, involvement hypergranulosis, vacuolar 
changes and INKers 
Sebaceous glands Absent Absent 
Arrector pili muscle Retained Diminished 
Variable dense lymphocytic Lichenoid lymphocytic Perifollicular inflammation infiltration at infundibulum perifollicular infiltration 
and isthmus 
Follicular INKers Absent Present 
Perivascular inflammation Lymphocytic infiltrate Lymphocytic infiltrate 
Premature desquamation of Present in early stage, along Present together with 
inner root sheath (PDIRS) with thinning of follicular inflammatory damage 
epithelium 
Follicular asymmetry and Present Present polytrichia 
Naked hair shaft Present Present 
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Concentric lamellar Present Present perifollicular fibrosis 
Clefting between stroma and Absent May present follicular epithelium 
Perifollicular mucin May present May present 
Elastin change Thicken dermal elastic fiber Loss of elastin in papillary in hyalinized dermis dermis 
Table 11. Summary of distinctive histologic findings of CCCA and LPP 
Histologic findings CCCA LPP p-value 
Presence of normal follicular units 58% 0% 0.04 
Complete loss of sebaceous glands 10% 60% 0.04 
Moderate to severe perifollicular 10% 60% 0.04 inflammation 
Dilatation of eccrine ducts 10% 60% 0.04 
90 
Table 12. Demographic data of patients with CCCA and LPP in study 2 
Characteristics CCCA,N=4 LPP,N=7 
Sex 
Female 4 (100%) 5 (71 %) 
Male 0 2(29%) 
Ethnicity 
African American 4 (100%) 0 
Caucasian 0 7 (100%) 
Mean age (range) 40.3 years (28-59) 54.3 years (37-72) 
Mean duration of disease 7 years (2-20) 3.2 years (1-7) 
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Table 13. Immunofluorescence results 
Case lgG IgM IgA C3 fibrinogen 
LGP-001 Negative Negative Negative Negative Negative 
LGP-002 Negative Negative Negative Negative Negative 
LGP-003 Negative Negative Negative Negative Negative 
Linear/ Shaggy 
LGP-004 shaggy deep Negative Negative Negative deep PF 
PF deposits deposits BMZ/PFCT 
LGP-005 Negative Negative Negative Negative Negative 
LGP-006 Negative Negative Negative Negative Negative 
Shaggy PF 
LGP-007 Negative Negative Negative deposits at Negative infundibulu 
m/isthmus 
Shaggy/ Shaggy/ 
LGP-008 granular PF Negative Negative granular PF Negative deposits at deposits at 
isthmus isthmus 
LGP-009 Negative Negative Negative Negative Negative 
LGP-010 Negative Negative Negative Negative Negative 
LGP-011 Negative Negative Negative Negative Negative 
PF = perifollicular, BMZ=basement membrane zone, CT = connective tissue 
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Table 14. DIF results and clinical history 
Duration of Perifollicular Previous Case DIF result Diagnosis disease, inflammation 
year(s) /erythema treatment 
LGP-001 Negative LPP 2 Mild 
ILK, 
doxycycline 
LGP-002 Negative LPP 1 Mild Topical 
steroid 
LGP-003 Negative LPP 1 Mild ILK 
IgG& 
LGP-004 fibrinogen LPP 2 Moderate Minoxidil 
positive 
LGP-005 Negative LPP 7 Mild Topical 
steroid 
LGP-006 Negative CCCA 2 Mild ILK, topical 
steroid 
LGP-007 C3 positive CCCA 3 Moderate Topical 
steroid 
LGP-008 IgG & C3 LPP 2.5 Moderate Topical positive steroid 
Plaquenil , 
LGP-009 Negative LPP 7 Mild topical 
steroid 
LGP-010 Negative CCCA 20 Mild None 
LGP-011 Negative CCCA 3 Mild Topical 
steroid 
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Table 15. Immunofluorescence results in the LPP group 
Case IgG IgM IgA C3 fibrinogen 
LGP-001 Negative Negative Negative Negative Negative 
LGP-002 Negative Negative Negative Negative Negative 
LGP-003 Negative Negative Negative Negative Negative 
Linear/ Shaggy deep LGP-004 shaggy deep Negative Negative Negative 
PF deposits PF deposits 
LGP-005 Negative Negative Negative Negative Negative 
Shaggy/ Shaggy/ 
LGP-008 granular PF Negative Negative granular PF Negative deposits at deposits at 
isthmus isthmus 
LGP-009 Negative Negative Negative Negative Negative 
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Table 16. Immunofluorescence results in the CCCA group 
Case IgG lgM lgA C3 fibrinogen 
LGP-006 Negative Negative Negative Negative Negative 
Shaggy PF 
LGP-007 Negative Negative Negative deposits at Negative infundibulu 
m/isthmus 
LGP-010 Negative Negative Negative Negative Negative 
LGP-011 Negative Negative Negative Negative Negative 
Table 17. DIF findings in LPP from previous studies 
Deposition at 
Deposition at DEJ of DEJof 
Author, year Number follicular epithelium, interfollicular Presence of 
of cases number of positive epithelium, cytoid body 
cases number of 
positive cases 
Ioannides67 , IgG 3/7, IgA 217, 
1992 7 lgG+IgA 117, None Negative IgG+IgM+fibrinogen1/7 
(linear pattern) 
Mehregan21 , Fibrinogen 9/28, IgM IgM+lgA, 1992 28 2/28, C3 1/28 (Patchy lgG 7/28 
pattern) rare C3 18/28 
Chieregato25 , 30 Non-specific, 17/30 Fibrinogen, lgM 13/30 2003 13/30 
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Table 18. Direct Immunofluorescence findings inlichen planus and LPP, as reported 
by Ioannides and Bystryn 67 
Lichen planus Lichen planopilaris (LPP) 
- Fibrinogen deposits in fibrillar pattern at - Linear IgG at BMZ of follicles 
basement membrane zone (BMZ) , more 70% with IgG or IGA 
than 90% of cases 30% with IgG +others 
- Ig and/or complement deposits at cytoid - 14% present with linear fibrin at 
body at BMZ, more than 90% of cases BMZ 
-Negative cytoid body 
Table 19. Demographic data of LPP patients in Study 3 
Case number Ethnicity Age, year Sex Duration of disease 
LGP-001 Caucasian 64 Male 2 years 
LGP-002 Caucasian 47 Female 1 year 
LGP-003 Caucasian 54 Female 1 year 
LGP-004 Caucasian 38 Female 2 years 
LGP-005 Caucasian 72 Female 7 years 
LGP-008 Caucasian 68 Female 2.5 years 
LGP-009 Caucasian 37 Male 7 years 
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Table 20. Demographic data of CCCA patients in Study 3 
Case number Ethnicity Age, year Sex Duration 
of disease 
African 
LGP-006 28 Female 2 years 
American 
African 
LGP-007 36 Female 3 years 
American 
African 
LGP-010 38 Female 20 years 
American 
LGP-011 Caucasian 59 Female 3 years 
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Table 21. Number of positive cells from photos of immunohistochemical stain 
Case CD3 CD4 CD8 CCR6 FoxP3 CD1a 
LGP-001 134 78 45 43 0 1 
LGP-002 39 14 19 18 0 4 
LGP-003 62 8 31 13 2 11 
LGP-004 llO 44 14 6 2 27 
LGP-005 9 5 9 6 2 1 
LGP-006 122 37 45 9 1 13 
LGP-007 86 30 34 15 2 1 
LGP-008 340 132 132 55 1 2 
LGP-009 206 140 108 44 2 2 
LGP-010 48 23 15 22 4 6 
LGP-Oll 203 129 24 42 1 7 
124 58 43 25 2 7 
Mean 
(9-340) (5-140) (9-132) (6-55) (0-4) (1-27) 
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Table 22. LPP. Number of positive cells from photos of immunohistochemical stains 
Case CD3 CD4 CD8 CCR6 FoxP3 CD1a 
LGP-001 134 78 45 43 0 1 
LGP-002 39 14 19 18 0 4 
LGP-003 62 8 31 13 2 11 
LGP-004 110 44 14 6 2 27 
LGP-005 9 5 9 6 2 1 
LGP-008 340 132 132 55 1 2 
LGP-009 206 140 108 44 2 2 
Mean 129 60 51 26 1 7 (9-340) (5-140) (9-132) (6-55) (0-2) (1-27) 
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Table 23. CCCA. Number positive cells from photos of immunohistochemical stains 
Case CD3 CD4 CDS CCR6 FoxP3 CD1a 
LGP-006 122 37 45 9 1 13 
LGP-007 86 30 34 15 2 1 
LGP-010 48 23 15 22 4 6 
LGP-011 203 129 24 42 1 7 
Mean 115 55 30 22 2 7 (48-203) (23-129) (15-45) (9-42) (1-4) (1-13) 
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Table 24. LPP. Percentages and ratios of positive cells from photos of 
immunohistochemical stains 
Case CD4% CD8% CCR6% FoxP3% CD4:CD8 CD1a:CD3 
LGP-001 58% 34% 32% 0% 1.73 0.01 
LGP-002 36% 49% 46% 0% 0.74 0.10 
LGP-003 13% 50% 21% 3% 0.26 0.18 
LGP-004 40% 13% 5% 2% 3.14 0.25 
LGP-005 56% 100% 67% 22% 0.56 0.11 
LGP-008 39% 39% 16% 0% 1.00 0.01 
LGP-009 68% 52% 21% 1% 1.30 0.01 
1.25 0.09 
44% 48% 30% 4% 
Mean (0.26- (0.01-
(13-68) (13-100) (5-67) (0-22) 
3.14) 0.25) 
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Table 25. CCCA. Percentages and ratios of positive cells from photos of 
immunohistochemical stains 
Case CD4% CD8% CCR6% FoxP3% CD4:CD8 CD1a:CD3 
LGP-006 30% 37% 7% 1% 0.82 0 .11 
LGP-007 35% 40% 17% 2% 0.88 0.01 
LGP-010 48% 31% 46% 8% 1.53 0.13 
LGP-011 64% 12% 21% 0% 5.38 0 .03 
2.15 0.07 
44% 30% 23% 3% 
Mean (0.82- (0.01-
(30-64) (12-40) (7-46%) (0-8%) 
5.38) 0.13) 
Table 26. LPP duration less than 1 year. Number of positive cells from photos of 
immunohistochemical stains 
Case CD3 CD4 CD8 CCR6 FoxP3 CD1a 
LGP-002 39 14 19 18 0 4 
LGP-003 62 8 31 13 2 11 
50.5 11 25 15.5 1 7.5 
Mean 
(39-62) (8-14) (19-31) (13-18) (0-2) (4-11) 
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Table 27. LPP duration greater than 1 year. Number of positive cells from photos 
of immunohistochemical stains 
Case CD3 CD4 CD8 CCR6 FoxP3 CD1a 
LGP-001 134 78 45 43 0 1 
LGP-004 110 44 14 6 2 27 
LGP-005 9 5 9 6 2 1 
LGP-008 340 132 132 55 1 2 
LGP-009 206 140 108 44 2 2 
159.8 79.8 61.6 30.8 1.4 6.6 
Mean 
(9-340) (5-140) (9-132) (6-55) (1-2) (1-27) 
Table 28. LPP duration less than 1 year. Percentages of T -cell subsets and ratios of 
positive cells from photos of immunohistochemical stains 
Case CD4% CD8% CD4:CD8 CCR6% FoxP3% CD1a:CD3 
LGP-002 36% 49% 0.74 46% 0% 0.10 
LGP-003 13% 50% 0.26 21% 3% 0.18 
0.50 
24% 49% 34% 2% 0.14 
Mean (0.26-
(13-36) (49-50%) (21-46) (0-2) (0.1-0.18) 
0.74) 
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Table 29. LPP duration over 1 year. Percentages ofT-cell subsets and ratios of 
positive cells from photos of immunohistochemical stains 
Case CD4% CD8% CD4:CD8 CCR6% FoxP3 % CD1a:CD3 
LGP-001 58% 34% 1.73 32% 0% 0 .01 
LGP-004 40% 13% 3.14 5% 2% 0.25 
LGP-005 56% 100% 0.56 67% 22% 0.11 
LGP-008 39% 39% 1.00 16% 0% 0 .01 
LGP-009 68% 52% 1.30 21 % 1% 0.01 
52% 48% 1.55 28% 5% 0 .08 Mean (39-68) (13-100) (0.56- (5-67) (0-22) (0.07-3.14) 0.25) 
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APPENDIX 
Appendix 1 
Histopathologic data collection form-Isthmus & Infundibulum level 
Epidermal Involvement ( ) Present 
( ) Absent 
The number of terminal follicles 
The number of vellus follicles 
The number of fused follicles 
The number of follicular units 
The number of fibrous tracts ( ) Absent 
( ) 1-5 
( ) 6-10 
( ) >10 
Follicular asymmetry ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
Perifollicular fibrosis ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
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Mucin ( ) Present 
( ) Absent 
Perifollicular inflammation ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
Naked hair shaft ( ) Present 
( ) Absent 
Follicular individual necrotic ( ) Present 
keratinocytes (INKers) ( ) Absent 
Number of involved follicles 
Intrafollicular lymphocytes ( ) Present 
( ) Absent 
Number of involved follicles 
Perivascular inflammation ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
Plasma cells ( ) Present 
( ) Absent 
Dilatation of eccrine ducts ( ) Present 
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I ( ) Absent 
Inferior level (at dermal subcutaneous junction) 
The number of follicles 
The number of fibrous tracts ( ) Absent 
( ) 1-5 
( ) 6-10 
( ) >10 
Follicular asymmetry ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
Perifollicular fibrosis/mucin ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
Perifollicular inflammation ( ) Absent 
( ) 1+ 
( ) 2+ 
( ) 3+ 
PDIRS ( ) Present 
( ) Absent 
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Follicular INKers ( ) Present 
( ) Absent 
Number of involved follicles 
Intrafollicular lymphocytes ( ) Present 
( ) Absent 
Number of involved follicles 
Perivascular inflammation ( ) Absent 
( )1+ 
( ) 2+ 
( ) 3+ 
Plasma cells ( ) Present 
( ) Absent 
Appendix 2 
Direct immunofluorescent data collection 
Case IgG IgM IgA C3 Fibrinogen 
Patient #1 
Patient #2 
Patient #3 
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Appendix 3 
Details of tissue processing and immunohistochemical staining 
The dehydration process was accomplished by passing the each specimen through 
a series of increasing alcohol concentrations from 30% to and 100% for about two hours 
each. The specimen was then placed in a second 100% ethanol solution to ensure that all 
water was removed. After dehydration, the tissue blocks were transferred to pure paraffin 
in the oven for 1 hour and then into melted paraffin for an additional 2-3 hours. During 
this time, the tissue block was completely infiltrated with melted paraffin. The tissue was 
then placed into an embedding mold and melted paraffin was poured into the mold to 
form a block. The blocks were allowed to cool, were cut into three-micrometer sections 
using a microtome, and layered on a glass slide. These were stored in a labeled box in 
Skin Pathology Laboratory until the time of staining. Just prior to staining, sections 
mounted on glass slides were deparaffinized and rehydrated through a series of graded 
alcohol to water. 
For H&E staining, the slide was immersed in hematoxylin for 4 minutes , rinsed 
with water, immersed in 0.3% acid alcohol, rinsed with water, immersed in eosin for 2 
minutes. Once staining was complete they were run through alcohols and clearing 
solvents, dried, and coverslipped. 
For CD3, CD4, CD8 and CDla staining, after deparaffinization and rehydration 
the specimen was incubated with Peroxidase Block Reagent for 5 minutes at room 
temperature , rinsed with Phosphate-buffered saline (PBS), then incubated with the 
primary antibody (CD3, CD4, CD8 and CD1a, all at a concentration of 1 :50) for 20 
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minutes and rinsed. The slide was then incubated with horseradish peroxidase (HRP) 
solution for 20 minutes , rinsed and incubated with diaminobenzidine (DAB) peroxidase 
substrate solution for 10 minutes, rinsed and incubated with hematoxylin for 5 minutes 
and rinsed. Then, they were run through alcohols and clearing solvents, dried, and 
coverslipped. 
For CCR6, after deparaffinization and rehydration the specimen was incubated 
with peroxidase block solution for 10 minutes at room temperature, rinsed with PBS, then 
incubated with the primary antibody (concentration of 1:50) for 40 minutes and rinsed. 
Then the slide was then incubated with HRP solution for 20 minutes, rinsed and 
incubated with DAB peroxidase substrate solution for 7 minutes, rinsed, incubated with 
hematoxylin for 5 minutes , and rinsed. Once staining was complete they were run 
through alcohols and clearing solvents, dried, and coverslipped. 
For FoxP3, after deparaffinization and rehydration the specimen was incubated 
with DEEB for 10 minutes at room temperature, rinsed with PBS followed by incubation 
in the primary antibody (concentration of 1:500) for 30 minutes, and rinsed. Then the 
slides were incubated with goat probe solution for 20 minutes, rinsed twice with PBS, 
incubated with goat polymer solution for 20 minutes, rinsed twice with PBS , incubated 
with DAB peroxidase substrate solution for 7 minutes, rinsed, incubated with 
hematoxylin for 5 minutes, and rinsed. Once staining was complete, they were run 
through alcohols and clearing solvents, dried, and coverslipped. 
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Appendix 4 
Immunohistochemical staining antibodies in Study 3 
Incubation 
Antibody Clone Manufacturer Dilution time 
(minutes) 
CD3 F7.2.38 Dako 1:50 30 
CD4 4B12 Dako 1:50 30 
CD8 C8/144B Dako 1:50 30 
CD1a 010 Dako 1:750 30 
CCR6 MAB195 R&D Systems 1:50 40 
FoxP3 AF3240 R&D Systems 1:500 30 
Appendix 5 
Immunoperoxidase data collection 
Case CD3 CD4 CD8 CCR6 FoxP3 CD1a 
Patient #1 
Patient #2 
Patient #3 
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